<allTrials totalCount="205" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2026-11-19T14:45:41.423176828Z" version="11" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN12271865" publicIdentifierDateAssigned="2026-11-19T14:56:13.166266Z">
    <isrctn dateAssigned="2026-11-19T14:56:13.166266Z">12271865</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Primed to eat: experimental effects of food marketing on salivation and consumption</title>
      <scientificTitle>Taste &amp; mood: exploring physiological and emotional responses to advertisements</scientificTitle>
      <acronym/>
      <studyHypothesis>Exposure to food advertising impacts food intake in children and adults. Multiple studies show that following food advertisements, compared with non-food advertisements, participants consume a greater amount of energy. The intake response has been shown to occur following exposure to both food cues and brand imagery, via mechanisms including both physiological and psychological effects. This evidence underpins new food advertising restrictions in the UK, where advertisements for high in fat, salt, and/or sugar (HFSS) food products (in regulated categories) cannot be shown on television before 9 pm or in paid-for advertising online at any time. However, brand advertising – advertisements that promote a brand, including the brand of a range of products – is exempt from these rules.

This study aims to measure the effect of exposure to food-range and brand-range advertisements on salivation and caloric intake.</studyHypothesis>
      <plainEnglishSummary>Background and study aims:
Food advertising can influence what people choose to eat and how much they eat. Previous research has suggested that seeing advertisements for food can increase the amount of food people subsequently consume. This evidence has contributed to restrictions on advertising foods that are high in fat, salt and sugar (HFSS) in the UK. However, some forms of food advertising, particularly advertisements that promote food brands rather than specific products, are not covered by the same restrictions.
This study aims to investigate whether different types of food advertising influence people's physical and eating responses. In particular, it will examine whether seeing food advertisements affects how much saliva people produce and how much food they subsequently eat.
The study will compare three types of advertising: advertisements showing a range of food products, advertisements promoting food brands with little or no specific food product imagery, and advertisements for non-food products. By comparing these three groups, the researchers hope to better understand whether different forms of food marketing influence eating behaviour.

Who can participate?
Adults aged 18 years and over from the general public and the University of Liverpool who like the snack food used in the study (Walkers Ready Salted crisps)

What does the study involve?
People interested in taking part will first complete a short screening questionnaire to check whether they meet the eligibility criteria. Those who are eligible will be invited to attend a single session at the University of Liverpool, lasting about 45 minutes. Before starting, participants will receive information about the study and will be asked to provide their informed consent.
Participants will first answer some questions about themselves and complete a short questionnaire about their mood. They will then provide a saliva sample by holding pre-weighed cotton rolls underneath their tongue for 60 seconds.
Participants will subsequently watch a series of short advertisements on a computer screen. They will be randomly allocated to one of three groups, meaning that each participant will see either advertisements for food (brand only) OR food (brand of a range) OR non-food.The advertisements will last about 9 minutes in total.
After watching the advertisements, participants will provide a second saliva sample using the same method. This will allow the researchers to compare the amount of saliva produced before and after watching the advertisements.
Participants will then be offered a portion of Walkers Ready Salted crisps as part of a taste-rating task. They will be free to eat as much or as little as they wish. The researchers will measure how much food has been eaten by weighing the crisps before and after the session.
Participants will also complete a short questionnaire about their mood and take part in an advertisement recognition task to assess which advertisements they remember seeing. Finally, they will be asked some questions about what they think the study was investigating.
At the end of the session, the researcher will explain the true purpose of the study and provide participants with an opportunity to ask questions.

What are the possible benefits and risks of participating?
There are no expected direct health benefits from taking part in this study. However, participation will help researchers improve their understanding of how different forms of food advertising may influence eating behaviour. This research may contribute to a better understanding of food marketing and inform future discussions about food advertising and public health.
First-year Psychology students at the University of Liverpool who participate through the department's research participation scheme may receive course credit in recognition of their involvement. Other students and members of the public will be able to contribute to psychological research and gain experience of taking part in a scientific study. No financial payment will be provided for participation.
The study is considered low risk. However, there are some potential risks and minor inconveniences associated with taking part. These include the possibility of choking while eating the crisps, as well as potential discomfort associated with saliva collection or eating the test food. Participants with known food allergies or intolerances will not be eligible to take part. The study will be conducted in a laboratory environment, and appropriate precautions will be taken to minimise potential risks. Participants will also be free to stop taking part at any time if they feel uncomfortable.

Where is the study run from?
University of Liverpool (UK)

When is the study starting and how long is it expected to run for?
November 2026 to June 2027

Who is funding the study?
University of Liverpool (UK)

Who is the main contact?
Mr Jonathan Oliveira, Jonathan.Oliveira@liverpool.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="5218bded-41aa-4349-9245-caccc5dfbca6">
	  <variable>Salivation</variable>
	  <method>dental cotton rolls</method>
	  <timepoints>before and after advertisement exposure</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="96335651-95fa-4f18-808c-a6a0cbe02a1f">
	  <variable>Eating intake</variable>
	  <method>caloric (kcal) total consumed of test food</method>
	  <timepoints>once after advertisement exposure</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="d1e66d36-a848-46f9-870c-43e38ad0938c">
	  <variable>Demographic characteristics</variable>
	  <method>questionnaire</method>
	  <timepoints>after consent form</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="6fb6820e-ea3d-41b5-84bb-3c6530fad441">
	  <variable>Hunger</variable>
	  <method>visual analogue scale (VAS)</method>
	  <timepoints>baseline, after advertisement exposure, and after eating intake</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="61e70cfb-2ce5-40f4-85c8-c0f92467032b">
	  <variable>External eating</variable>
	  <method>the Dutch Eating Behavioural Questionnaire</method>
	  <timepoints>the end of the study</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="cffac2d7-741b-4436-b518-aeee40454a02">
	  <variable>Aims guessing</variable>
	  <method>open text response</method>
	  <timepoints>before the debrief</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="15b3d270-3671-44b8-b42d-251c1945d977" approvalStatus="approved" statusDate="2026-11-13T00:00:00.000Z">
	  <committeeName>Central University Research Ethics Committee D (CUREC-D)</committeeName>
	  <contactDetails>
	    <address>University of Liverpool
Foundation Building
765 Brownlow Hill</address>
	    <city>Liverpool</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>L69 7ZX</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>17300 (amendment)</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12271865</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber/>
      <secondaryNumbers/>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Basic science</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2027-06-18T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a164950f-86af-43d7-a7b4-832d3531bade">
	  <name>University of Liverpool</name>
	  <address>Eleanor Rathbone Building 
74 Bedford Street South</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L69 7ZA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>true</healthyVolunteersAllowed>
      <inclusion>1. Aged 18 years or over
2. United Kingdom (UK) resident
3. Fluent in English
4. Self-reported liking of test foods</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="99.0">99 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>186</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Dietary restrictions other than vegetarian (e.g., Vegan, gluten-free, sugar-free, dairy/lactose-free)
2. Food allergies/ intolerances (e.g., milk, eggs, nut, wheat, fish etc)
3. Current or historic diagnosed eating disorder
4. Currently dieting
5. Auditory or (non-corrected) vision impairments
6. Taking any medication which may influence taste, salivation or appetite (excluding the contraceptive pill)
7. Current of past diagnosed psychological or mental health condition
8. Smoking (including the use of e-cigarettes)</exclusion>
      <recruitmentStart>2026-11-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-06-04T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Public health prevention of commercial determinants of health</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This study will utilise a between-subjects design, with an independent variable of advertisement condition (food-brand only, food-brand of a range, or non-food control). The primary dependent variables will be eating intake (kcal), and change in salivation (calculating the difference in participants’ saliva measurements before versus after advertising exposure).

Participants will be randomly allocated to an experimental condition, sequenced using a random number generator (https://www.random.org/sequences/). A cover story will be used to reduce awareness of study aims. Specifically, participants will be told that the study is investigating the effect of advertisement media on mood and taste perceptions. Measures of mood and taste ratings will be taken in accordance with the cover story, but these data will be discarded and not analysed.

People interested in taking part will first complete a short screening questionnaire to check whether they meet the eligibility criteria. Those who are eligible will be invited to attend a single session at the University of Liverpool, lasting about 45 minutes. Before starting, participants will receive information about the study and will be asked to provide their informed consent.

Participants will first answer some questions about themselves and complete a short questionnaire about their mood. They will then provide a saliva sample by holding pre-weighed cotton rolls underneath their tongue for 60 seconds.

Participants will subsequently watch a series of short advertisements on a computer screen. They will be randomly allocated to one of three groups, meaning that each participant will see either advertisements for food (brand only) OR food (brand of a range) OR non-food.The advertisements will last about 9 minutes in total.

After watching the advertisements, participants will provide a second saliva sample using the same method. This will allow the researchers to compare the amount of saliva produced before and after watching the advertisements.

Participants will then be offered a portion of Walkers Ready Salted crisps as part of a taste-rating task. They will be free to eat as much or as little as they wish. The researchers will measure how much food has been eaten by weighing the crisps before and after the session.

Participants will also complete a short questionnaire about their mood and take part in an advertisement recognition task to assess which advertisements they remember seeing. Finally, they will be asked some questions about what they think the study was investigating.

At the end of the session, the researcher will explain the true purpose of the study and provide participants with an opportunity to ask questions.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a18d93d5-50a7-458a-be34-b499227b88df" outputType="otherfiles" artefactType="LocalFile" dateCreated="2026-11-09T00:00:00.000Z" dateUploaded="2026-11-19T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="2e1db90c-b3eb-4509-94d7-3d2ab847118d" originalFilename="50683_RiskAssessment_V2_09Nov2026.pdf" downloadFilename="50683_RiskAssessment_V2_09Nov2026.pdf" version="2" mimeType="application/pdf" length="68794" md5sum="9923d5081be6c2f9a2f36c575fc1a095"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="0466598b-0fe8-4eaf-a970-2ccf36819f55" outputType="otherfiles" artefactType="LocalFile" dateCreated="" dateUploaded="2026-11-19T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="909734e8-e960-4cd2-bbeb-666146591bea" originalFilename="50683_DebriefSheet.pdf" downloadFilename="50683_DebriefSheet.pdf" version="" mimeType="application/pdf" length="214246" md5sum="ea26083e56ca1f26ca4a079dff0c6ba0"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="76260da2-dd17-42e1-a5ae-24bfc5cdd008" outputType="otherfiles" artefactType="LocalFile" dateCreated="" dateUploaded="2026-11-19T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="8f596f3e-2af5-48ba-b124-91d2a1d073b8" originalFilename="50683_ConsentForm_V2.pdf" downloadFilename="50683_ConsentForm_V2.pdf" version="2" mimeType="application/pdf" length="110409" md5sum="a9a3cc7e569cc3dadde475f2d9740c8b"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="40395eda-0e72-447f-9bbc-2f658b78fc84" outputType="pis" artefactType="LocalFile" dateCreated="" dateUploaded="2026-11-19T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="1e7ff28a-84ce-450e-ab84-eed042ecd373" originalFilename="50683_PIS_V3.pdf" downloadFilename="50683_PIS_V3.pdf" version="3" mimeType="application/pdf" length="201035" md5sum="3fe22b3927b323b984006f1e28ab025f"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="2910bb39-04f8-44e9-8fd2-724290d89cef" outputType="protocolfile" artefactType="LocalFile" dateCreated="" dateUploaded="2026-11-19T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="79e8934b-d5cc-45ba-a4c6-ff8b64dcc5bd" originalFilename="50683_PROTOCOL.pdf" downloadFilename="50683_PROTOCOL.pdf" version="" mimeType="application/pdf" length="257277" md5sum="e20e3907cb1d4da1a03f4f72b534caa3"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>81dad503-3d43-4a43-87d2-ef988d071df2</funderId>
      <contactId>0c9a5e9d-d0b0-4999-b2c2-4427daa20b38</contactId>
      <contactId>c807cf8e-c0f5-46ab-a55e-377310f89870</contactId>
      <sponsorId>da155fb0-35ed-43c6-967a-484fb410aa93</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/79e8934b-d5cc-45ba-a4c6-ff8b64dcc5bd/50683">
	<description>Protocol file</description>
	<name>50683_PROTOCOL.pdf</name>
	<id>79e8934b-d5cc-45ba-a4c6-ff8b64dcc5bd</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>257277</length>
	<md5sum>e20e3907cb1d4da1a03f4f72b534caa3</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/2e1db90c-b3eb-4509-94d7-3d2ab847118d/50683">
	<description>Other files</description>
	<name>50683_RiskAssessment_V2_09Nov2026.pdf</name>
	<id>2e1db90c-b3eb-4509-94d7-3d2ab847118d</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>68794</length>
	<md5sum>9923d5081be6c2f9a2f36c575fc1a095</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/909734e8-e960-4cd2-bbeb-666146591bea/50683">
	<description>Other files</description>
	<name>50683_DebriefSheet.pdf</name>
	<id>909734e8-e960-4cd2-bbeb-666146591bea</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>214246</length>
	<md5sum>ea26083e56ca1f26ca4a079dff0c6ba0</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/8f596f3e-2af5-48ba-b124-91d2a1d073b8/50683">
	<description>Other files</description>
	<name>50683_ConsentForm_V2.pdf</name>
	<id>8f596f3e-2af5-48ba-b124-91d2a1d073b8</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>110409</length>
	<md5sum>a9a3cc7e569cc3dadde475f2d9740c8b</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/1e7ff28a-84ce-450e-ab84-eed042ecd373/50683">
	<description>Participant information sheet</description>
	<name>50683_PIS_V3.pdf</name>
	<id>1e7ff28a-84ce-450e-ab84-eed042ecd373</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>201035</length>
	<md5sum>3fe22b3927b323b984006f1e28ab025f</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="0c9a5e9d-d0b0-4999-b2c2-4427daa20b38">
    <title>Mr</title>
    <forename>Jonathan</forename>
    <surname>Oliveira</surname>
    <orcid>https://orcid.org/0009-0004-4212-0497</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Eleanor Rathbone Building
74 Bedford Street South</address>
      <city>Liverpool</city>
      <state/>
      <country>United Kingdom</country>
      <zip>L69 7ZA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)151 794 9820</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Jonathan.Oliveira@liverpool.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="c807cf8e-c0f5-46ab-a55e-377310f89870">
    <title>Prof</title>
    <forename>Emma</forename>
    <surname>Boyland</surname>
    <orcid>https://orcid.org/0000-0001-8384-4994</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Eleanor Rathbone Building
74 Bedford Street South</address>
      <city>Liverpool</city>
      <state/>
      <country>United Kingdom</country>
      <zip>L69 7ZA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)151 794 1137</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">E.Boyland@liverpool.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="da155fb0-35ed-43c6-967a-484fb410aa93">
    <organisation>University of Liverpool</organisation>
    <sponsorType/>
    <rorId>https://ror.org/04xs57h96</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="81dad503-3d43-4a43-87d2-ef988d071df2">
    <name>University of Liverpool</name>
    <fundRef>http://dx.doi.org/10.13039/501100000836</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-10T12:11:21.391206501Z" version="9" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN99442139" publicIdentifierDateAssigned="2026-11-10T12:11:21.589485Z">
    <isrctn dateAssigned="2026-11-10T12:11:21.589485Z">99442139</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multimodal approach to preventing suicide in schools project</title>
      <scientificTitle>Multimodal Approach to Preventing Suicide in Schools (MAPSS) project: a randomised controlled trial</scientificTitle>
      <acronym>MAPSS</acronym>
      <studyHypothesis/>
      <plainEnglishSummary>Suicide is the leading cause of death in young people under 35 in England. The impact of suicide on a young person’s family, friends, and wider community can be devastating and can also increase their own risk of suicide. The Government guidance for youth suicide prevention programmes does not meet the needs of young people at the moment. There is an urgent need to develop and test suitable ways to prevent suicide in young people.

We plan to deliver a suicide prevention programme in secondary schools across England. This programme, known as the “Multimodal Approach to Preventing Suicide in Schools” (MAPSS), has been tested in six schools in Cheshire and Merseyside with Year 10 pupils (aged 14-15). MAPSS involves delivering a suicide awareness lesson (‘Breaking the Silence’) to all students, then assessing them for suicide risk, and then having an online Cognitive Behavioural Therapy programme (‘Reframe IT-UK’) for students who score at high-risk for suicide.

We have completed a study to test if MAPSS is safe and suitable in the UK with 889 students. Findings showed that MAPSS was safe to deliver, with most students saying they found it useful and would recommend it. Depression, quality of life, and if students may seek help improved for those taking part in the programme. We also found that it would be possible to conduct a larger trial of MAPSS in the UK.

Students and staff reported that suicide prevention should start earlier than Year 10 and that it would be easier to deliver in younger year groups who are not completing GCSEs. For this reason, this next trial will be conducted in Year 9 (13-14 years).
We will carry out a 4-year effectiveness trial in 36 schools. Teachers and parents will complete free training delivered by the suicide prevention charity ‘Papyrus’. Next, schools will be randomly put into two groups. One group will receive the MAPSS intervention (18 schools), and the other will continue with their usual practice only (i.e., control; 18 schools).

Students in MAPSS schools will receive the suicide awareness lesson. Students in all schools will then complete a survey to identify any who may be at high risk of suicide. High risk students in MAPSS schools will be offered Reframe IT-UK, and students in control schools will be offered usual care from their school. All students in MAPSS and control schools will complete surveys before and after the suicide prevention lesson, after Reframe IT-UK, and one-year later, to see whether MAPSS can help reduce suicidal thoughts, improve help-seeking, and increase knowledge, compared to usual practice.

We will also interview students, teachers, and staff leading the suicide prevention lessons to better understand their experiences and views about MAPSS.

Public advisors have been involved in designing this study and will be involved all the time. Three parents with lived experience, the '3 dads walking', and youth clubs supporting young people at risk of suicide are working with us; to make sure that young people’s voices are heard. Young people (aged 14-18 years) have helped with designing study videos, surveys and information sheets. A public representative will be leading and co-ordinating a young people’s advisory group for the study.

We will share our findings in co-developed journal articles, policy evidence briefings, international conferences, tailored reports for parents, children, and education professionals, and videos.</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="e663aec4-20a9-4f9e-baa2-f86f3e033df7">
	  <variable>Help-seeking intentions for suicidal thoughts and suicidal thoughts</variable>
	  <method>General Help-Seeking Questionnaire (GHSQ) and Suicide Ideation Attributes Scale (SIDAS)</method>
	  <timepoints>Baseline (T1), 2-4 weeks post-baseline (T2), 12 weeks post-baseline (T3), 1-year post-baseline (T4)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="ae707d39-8ad2-41b9-ab93-df3dc5d0d3e3">
	  <variable>Adverse events</variable>
	  <method>Adverse event monitoring</method>
	  <timepoints>Baseline (T1), 2-4 weeks post-baseline (T2), 12 weeks post-baseline (T3), 1-year post-baseline (T4)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="8acb5570-91cf-4b15-9526-e99e59703474">
	  <variable>Healthcare costs and service resource use (including attendances to GP, Emergency Department (ED), Child and Adolescent Mental Health Services (CAMHS), other community mental health services, hospital admissions, contacts with school nurses, counsellors, social workers and helplines)</variable>
	  <method>Adapted Young Minds Matter Service Use Questionnaire</method>
	  <timepoints>Baseline (T1), 2-4 weeks post-baseline (T2), 12 weeks post-baseline (T3), 1-year post-baseline (T4)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="94096a54-4bf4-48b3-b0df-8220a04e07b2">
	  <variable>Cost of delivering MAPSS components (including training, BtS workshop delivery, screening for high-risk students and REFRAME-IT UK delivery)</variable>
	  <method>Interviews supplemented by evidence from the Service Use Questionnaire</method>
	  <timepoints>2-4 weeks post-baseline (T2), 12 weeks post-baseline (T3)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="56f016bd-7b9a-43ff-abee-43ace00aded3">
	  <variable>Cost of delivering usual care</variable>
	  <method>Bespoke Usual Practice Survey</method>
	  <timepoints>Baseline (T1), 12 weeks post-baseline (T3)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="79de04f3-5d90-4a3c-91b7-a4491fef297e">
	  <variable>Health-related quality of life (QoL) and quality-adjusted life years (QALYs)</variable>
	  <method>Child Health Utility-9D (CHU9D)</method>
	  <timepoints>Baseline (T1), 2-4 weeks post-baseline (T2), 12 weeks post-baseline (T3), 1-year post-baseline (T4)</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="d69da371-c9c0-477c-b185-70119df998b6">
	  <variable>Suicide literacy</variable>
	  <method>Literacy of Suicide Scale (LOSS)</method>
	  <timepoints>Baseline (T1), 2-4 weeks post-baseline (T2), 12 weeks post-baseline (T3), 1-year post-baseline (T4)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="5b01468b-51ab-49ef-b3d5-7960b3d8e280">
	  <variable>Identification of students at risk of suicide who had not previously sought help</variable>
	  <method>Patient Health Questionnaire-9 (PHQ-9) and Suicide Ideation Attributes Scale (SIDAS)</method>
	  <timepoints>PHQ-9 at Baseline (T1), 2-4 weeks post-baseline (T2), 12 weeks post-baseline (T3), 1-year post-baseline (T4); SIDAS at 2-4 weeks post-baseline (T2) and 12 weeks post-baseline (T3)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="822dc719-479d-412b-bd17-d1928ca337e1">
	  <variable>Suicidal thoughts, depression, and hopelessness</variable>
	  <method>Suicide Ideation Attributes Scale (SIDAS), Patient Health Questionnaire-9 (PHQ-9), and Brief-H-Pos</method>
	  <timepoints>Baseline (T1), 2-4 weeks post-baseline (T2), 12 weeks post-baseline (T3), 1-year post-baseline (T4)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="f76264e0-fc61-4ece-9159-cc9a6d4c7c42">
	  <variable>Feasibility for sustainability and future scaling-up</variable>
	  <method>Qualitative interviews and focus groups with key stakeholders</method>
	  <timepoints>the end of the study</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="b9d0a917-fbc5-4bb9-bfd1-53bc46190bc3" approvalStatus="notYetSubmitted">
	  <committeeName/>
	  <contactDetails>
	    <address/>
	    <city/>
	    <state/>
	    <country/>
	    <zip/>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference/>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99442139</doi>
      <eudraCTNumber/>
      <irasNumber>375140</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 75361, NIHR: 507343</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="d643c39b-7b51-46dd-a0f0-ed649d1ef1ed" numberType="iras" canonicalSecondaryNumber="IRAS375140">375140</secondaryNumber>
	<secondaryNumber id="d77f9dab-d1e2-4c9e-97e7-247726829674" numberType="cpms" canonicalSecondaryNumber="CPMS75361">75361</secondaryNumber>
	<secondaryNumber id="0747bd52-2f85-4ac8-8823-45b37742ea58" numberType="nihr" canonicalSecondaryNumber="NIHR507343">507343</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Cluster</assignment>
	<purposes>
	  <purpose>Basic science</purpose>
	  <purpose>Prevention</purpose>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2030-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1ed07cee-6894-49af-818f-928a6ddcfb28">
	  <name>Schools</name>
	  <address>TBC</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L3 3AF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>true</healthyVolunteersAllowed>
      <inclusion>Year 9 school pupils in recruited MAPSS schools</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="years" value="13.0">13 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="14.0">14 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>5400</targetEnrolment>
      <totalFinalEnrolment>5400</totalFinalEnrolment>
      <exclusion>Does not meet inclusion criteria</exclusion>
      <recruitmentStart>2027-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2029-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Preventing suicide in schools</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention delivery will be funded by Grassroots Suicide Prevention. MAPSS consists of three components delivered sequentially:
1.	Breaking the Silence (BtS), a universal psychoeducation lesson developed by Grassroots Suicide Prevention charity between timepoint 1 (T1; baseline) and T2.27 BtS is a suicide alertness training workshop, suitable for anyone over the age of 11. It comprises a 2-hour face-to-face interactive workshop, designed to help participants understand suicide warning signs in themselves and others, gain knowledge about sources of support, and know how to signpost others to support. BtS workshops will be delivered by trained Grassroots facilitators to classroom-sized groups of students (maximum 30 per session).
2.	Screening takes the form of self-report measures embedded into the trial surveys at T2. Students indicating either suicidal ideation within the past 4 weeks on the Suicide Ideation Attributes Scale (SIDAS22; score ≥21 [see measures]) or reporting suicidal ideation on a single item of the PHQ928 are considered ‘at-risk’. At-risk students are flagged with the school and supported by the school pastoral team within 24 hours. At-risk students receiving the intervention are then offered Reframe IT-UK.
3.	Reframe IT-UK is an Australian evidence-based programme adapted for use in the UK20, delivered between T2 and T3. It comprises eight 20-minute online self-guided CBT modules, following the stories of two young people who make video diaries about their day-to-day life and their experience of feeling suicidal. There is also a safety plan, message board through which the participants can communicate with a moderator, a mood diary, and signposting information. Modules are completed during school time with pastoral staff.  As part of the trial, staff will receive clinical supervision while delivering Reframe IT-UK to ensure safety, adherence to the programme, and to monitor any variability in implementation.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>2ac44dbb-3e1f-42bc-b868-ae603187ca5b</funderId>
      <contactId>5dae6333-59b2-40d7-b416-89dd080eedaf</contactId>
      <contactId>71ff217e-9a7d-49a0-bcdb-f9cb0f9b1edf</contactId>
      <contactId>ca069a44-6e2e-4427-be79-e2405ee82efd</contactId>
      <sponsorId>4e46c14a-5225-4911-bb30-1ec37efee7e0</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="5dae6333-59b2-40d7-b416-89dd080eedaf">
    <title>Prof</title>
    <forename>Pooja</forename>
    <surname>Saini</surname>
    <orcid>https://orcid.org/0000-0002-4981-7914</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Byrom Street</address>
      <city>Liverpool</city>
      <state/>
      <country>United Kingdom</country>
      <zip>L3 3AF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 7946169335</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.saini@ljmu.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="71ff217e-9a7d-49a0-bcdb-f9cb0f9b1edf">
    <title>Dr</title>
    <forename>Emma</forename>
    <surname>Ashworth</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Byrom Street</address>
      <city>Liverpool</city>
      <state/>
      <country>United Kingdom</country>
      <zip>L3 3AF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 151 231 8121</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">e.l.ashworth@ljmu.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="ca069a44-6e2e-4427-be79-e2405ee82efd">
    <title>Dr</title>
    <forename>Molly</forename>
    <surname>McCarthy</surname>
    <orcid/>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Byrom Street</address>
      <city>Liverpool</city>
      <state/>
      <country>United Kingdom</country>
      <zip>L3 3AF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 151 231 8121</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">M.McCarthy1@ljmu.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="4e46c14a-5225-4911-bb30-1ec37efee7e0">
    <organisation>Liverpool John Moores University</organisation>
    <sponsorType/>
    <rorId>https://ror.org/04zfme737</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="2ac44dbb-3e1f-42bc-b868-ae603187ca5b">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-09T13:05:08.786595821Z" version="7" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN12410144" publicIdentifierDateAssigned="2026-11-09T13:05:09.027582Z">
    <isrctn dateAssigned="2026-11-09T13:05:09.027582Z">12410144</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Monitoring blood sugar levels in pregnancy: comparing continuous glucose monitoring with finger-prick testing for gestational diabetes</title>
      <scientificTitle>RandomisEd controlled trial of COntinuous Glucose moNItoring in the management of geStational Diabetes mellitus - a multi-centre randomised controlled trial</scientificTitle>
      <acronym>RECOGNISED</acronym>
      <studyHypothesis>Primary objective
Determine the difference between groups for adverse neonatal outcomes at birth (primary outcome; composite outcome of perinatal death, Neonatal Intensive Care Unit (NICU) admission and Large for Gestational Age (LGA) at 28 days post-natal)

Secondary objectives
1. Determine the difference between groups for other maternal and neonatal clinical, and maternal diabetes behaviour/health-related quality of life outcomes
2. Evaluate the cost-effectiveness of CGM compared with self monitoring of blood glucose (SMBG) testing
3. Assess the acceptability of, and obstacles and facilitators to, CGM use via diabetes treatment satisfaction, maternal quality of life and wellbeing outcomes using qualitative interviews and validated questionnaires to inform future implementation in the wider NHS</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Gestational diabetes mellitus (GDM) is a condition where blood sugar (glucose) levels become too high during pregnancy. Around 1 in 5 pregnant women in the UK develop GDM and this number is increasing each year. GDM is more common in women from minority ethnic backgrounds and those living on lower incomes. It can cause serious problems for mothers and babies, including early birth, babies growing too large or too small, admission to neonatal intensive care, and stillbirth or newborn death. Detecting and managing blood sugar levels reduces these risks and can lower costs to the NHS.

Currently, women with GDM monitor their blood sugar using finger‑prick tests, also called Self Monitoring of Blood Glucose (SMBG), several times a day. This can be painful and inconvenient and only provides limited information, leading to missed chances to reduce complications from GDM. Continuous Glucose Monitoring (CGM) could be a solution. CGM uses a small sensor worn on the arm to measure blood sugar continuously and send readings to a smartphone or reader. It is painless and provides blood sugar level information 24 hours a day that could help healthcare staff and women to lower blood sugar levels and reduce pregnancy complications. 

The RECOGNISED study will recruit pregnant women with GDM from 25 UK maternity centres. Participants will be assigned to one of two groups by randomisation, ensuring both groups are similar. One group will monitor their blood glucose using SMBG (usual care) and the other group will use CGM. RECOGNISED will assess whether monitoring blood glucose using CGM improves outcomes for mothers and babies, reduces NHS costs, and is acceptable to women and healthcare teams, when compared with the current standard of care (SMBG).

Who can participate?
Pregnant women diagnosed with GDM with no other forms of diabetes, and who are being cared for at any hospital participating in the RECOGNISED trial. 

What does the study involve?
Patients who agree to take part will be randomly assigned to monitor their blood glucose using SMBG or CGM until delivery. Participants will be asked to complete questionnaires when they are enrolled, at 34 weeks gestation and at 13 weeks postnatal. Usual care (SMBG) participants will additionally wear a blinded CGM sensor at enrolment and at 34 weeks gestation for two weeks. Some participants will have an additional blood test at 34 weeks gestation to measure HbA1c if that was not previously done as part of their usual care. The research team will also collect routine medical data for the participant (mother) and their baby from randomisation to 13 weeks postnatal. Participants may also take part in an interview to discuss their experiences of the study if they wish to.

What are the possible benefits and risks of participating?
Participants are unlikely to receive any direct benefit from taking part. However, the information collected may help researchers and healthcare professionals better understand different methods of monitoring blood glucose in women with gestational diabetes, which could improve care for future patients.
Participants may experience minor discomfort from using the sensors (e.g. bruising or skin irritation). There is a possibility of sensor malfunction or inaccurate readings, which may require temporary use of finger-prick blood glucose testing instead. Some questionnaires include questions about wellbeing and mental health, which some participants may find upsetting or distressing.

Where is the study run from?
The Bristol Trials Centre, a UK Clinical Research Collaboration registered Clinical Trials Unit, which is part of the University of Bristol’s Medical School, UK.

When is the study starting and how long is it expected to run for?
January 2027 to April 2029. Recruitment to the study is expected to start in January 2027 and will continue for 22 months. Following this, there will be 6 months of follow-up, so the study results will not be expected until the end of 2029.

Who is funding the study?
The National Institute of Health and Social Care Research (NIHR) – Health Technology Assessment Programme (NIHR-HTA), UK.

Who is the main contact?
The central trial team, recognised-study@bristol.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="8bbb4a2e-dbfd-426c-b070-b78066b20621">
	  <variable>A composite primary outcome of: perinatal death (stillbirth/neonatal death ≤28 days of life), NICU admission, and/or large for gestational age baby (LGA, &gt; 90th birth weight centile for gestational age),</variable>
	  <method>data collected from medical notes</method>
	  <timepoints>the delivery of the baby(ies) and at 28 days postnatal for all recruited participants</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="c3b64832-2ce7-4bc0-9a3f-b9d8b9310339">
	  <variable>Glucose control and glucose variability</variable>
	  <method>data collected from CGM devices from randomisation to delivery</method>
	  <timepoints>continuous time points</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="34f5535c-a305-4364-b615-d487c03ca727">
	  <variable>Long term glycaemic control</variable>
	  <method>an HbA1c blood test</method>
	  <timepoints>baseline, 34 weeks gestation and 13 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="a561a925-d1b2-42c9-b5b2-bf2af8278220">
	  <variable>Clinical maternal outcomes (pre-eclampsia, hypertension, weight gain, diabetes treatment, obstetric anal sphincter injury, miscarriage, termination of pregnancy and delivery admission length)</variable>
	  <method>data collected from medical notes</method>
	  <timepoints>baseline, 34 weeks gestation and delivery</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="d66afcc8-1e85-4a16-b026-064e78bb9661">
	  <variable>Clinical neonatal outcomes (components of primary outcome, duration of NICU stay, gestation at delivery, birth mode, neonatal morbidity, birth weight, feeding method, neonatal unit admissions)</variable>
	  <method>data collected from medical notes</method>
	  <timepoints>delivery and 4 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="2cca5d42-46fa-458b-b473-2155ff48515d">
	  <variable>Adverse events for mother and baby</variable>
	  <method>data reported/collected from medical notes</method>
	  <timepoints>from randomisation to 4 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="6d916642-8a92-4300-9c6c-b74d1374a7a1">
	  <variable>Maternal diabetes behaviour</variable>
	  <method>the Summary of Diabetes Self-Care Activities (SDSCA)</method>
	  <timepoints>baseline, 34 weeks gestation and 13 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="977c92d6-6c64-48c9-9ccd-51e9250d95b0">
	  <variable>Glucose monitoring satisfaction</variable>
	  <method>the Glucose Monitoring Experiences (GME-Q)</method>
	  <timepoints>34 weeks gestation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="7af72adc-721e-42ef-93fc-c7710f529980">
	  <variable>Depression</variable>
	  <method>the Patient Health Questionnaire 9-item depression scale (PHQ-9)</method>
	  <timepoints>baseline, 34 weeks gestation and 13 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="ecadd7ae-a411-4616-bf99-c46d1a153738">
	  <variable>Health-related quality of life</variable>
	  <method>the EQ-5D-5L</method>
	  <timepoints>baseline, 34 weeks gestation and 13 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="f4858db6-db57-4ede-a4c4-d4e675121ea6">
	  <variable>Maternal and neonatal/infant hospital admissions, outpatient visits and wider NHS resource use</variable>
	  <method>an NHS Resource Use Questionnaire and data collected from medical records</method>
	  <timepoints>from randomisation to 13 weeks postnatal</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="0b8f52a4-8f7c-48d4-9ee3-210cd5d0a3de" approvalStatus="submitted" statusDate="2026-10-26T00:00:00.000Z">
	  <committeeName>North West – Preston  Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/NW/0326</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12410144</doi>
      <eudraCTNumber/>
      <irasNumber>358288</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 68501, NIHR: 170211</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="997cc6a5-b504-4224-930f-aa658735a766" numberType="iras" canonicalSecondaryNumber="IRAS358288">358288</secondaryNumber>
	<secondaryNumber id="499a76f5-2b8c-4c61-8c29-1d170966f3f7" numberType="cpms" canonicalSecondaryNumber="CPMS68501">68501</secondaryNumber>
	<secondaryNumber id="5ea32a51-afb4-4110-9770-7712d82bc555" numberType="nihr" canonicalSecondaryNumber="NIHR170211">170211</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2029-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Wales</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cd2ced56-e6f3-408b-a11d-2ac4919e9c41">
	  <name>St. James's University Hospital</name>
	  <address>Beckett Street</address>
	  <city>Leeds</city>
	  <state/>
	  <country>England</country>
	  <zip>LS9 7TF</zip>
	</trialCentre>
	<trialCentre id="8c84510a-e44e-4025-8aa6-ac8cd0b8208f">
	  <name>Bradford Royal Infirmary</name>
	  <address>Chesnut House
Duckworth Lane</address>
	  <city>Bradford</city>
	  <state/>
	  <country>England</country>
	  <zip>BD9 6RJ</zip>
	  <rtsId>RR842@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="6a46c5e9-2e57-42ba-bda5-b1769eef3431">
	  <name>The Calderdale Royal Hospital</name>
	  <address>Huddersfield Road</address>
	  <city>Halifax</city>
	  <state/>
	  <country>England</country>
	  <zip>HX3 0PW</zip>
	</trialCentre>
	<trialCentre id="92cc9a7e-fcb1-49a8-a5a7-1e75ed86e29c">
	  <name>Liverpool Women's Hospital</name>
	  <address>Crown Street</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L8 7SS</zip>
	</trialCentre>
	<trialCentre id="208c4379-180b-441d-8465-35958b4bb529">
	  <name>Newham University Hospital</name>
	  <address>Glen Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>E13 8SL</zip>
	</trialCentre>
	<trialCentre id="661dcb5c-637b-4b05-a329-e15f6bf110fe">
	  <name>Leicester Royal Infirmary</name>
	  <address>Infirmary Square</address>
	  <city>Leicester</city>
	  <state/>
	  <country>England</country>
	  <zip>LE1 5WW</zip>
	  <rtsId>RFR0H@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="36b2fbff-b5f7-4cd6-83d2-9fea6134528f">
	  <name>Royal Derby Hospital</name>
	  <address>Uttoxeter Road</address>
	  <city>Derby</city>
	  <state/>
	  <country>England</country>
	  <zip>DE22 3NE</zip>
	  <rtsId>RTGFG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="65bf2eba-868a-4574-9dad-145389088fc3">
	  <name>Milton Keynes University Hospital</name>
	  <address>Milton Keynes Hospital
Standing Way
Eaglestone</address>
	  <city>Milton Keynes</city>
	  <state/>
	  <country>England</country>
	  <zip>MK6 5LD</zip>
	  <rtsId>RTH83@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="f8533210-2c51-449f-b963-a48b17c1b4e2">
	  <name>Norfolk and Norwich University Hospital</name>
	  <address>Colney Lane
Colney</address>
	  <city>Norwich</city>
	  <state/>
	  <country>England</country>
	  <zip>NR4 7UY</zip>
	  <rtsId>RCX09@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="393378a1-9b6e-4aa7-862e-4493a8bbcf35">
	  <name>Southmead Hospital</name>
	  <address>Southmead Road
Westbury-on-trym</address>
	  <city>Bristol</city>
	  <state/>
	  <country>England</country>
	  <zip>BS10 5NB</zip>
	</trialCentre>
	<trialCentre id="a7c8b4a6-91e6-4b58-bfe5-248992b9f9d4">
	  <name>Chelsea and Westminster Hospital</name>
	  <address>Doughty House
369 Fulham Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SW10 9NH</zip>
	</trialCentre>
	<trialCentre id="5e74ac1f-b5be-459a-bfdb-8d6b0bed22c2">
	  <name>West Middlesex University Hospital</name>
	  <address>Twickenham Road</address>
	  <city>Isleworth</city>
	  <state/>
	  <country>England</country>
	  <zip>TW7 6AF</zip>
	  <rtsId>NV182@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="cc2aa9f2-00b6-4dd8-a91e-3ee2099e563f">
	  <name>Royal Berkshire Hospital</name>
	  <address>London Road</address>
	  <city>Reading</city>
	  <state/>
	  <country>England</country>
	  <zip>RG1 5AN</zip>
	  <rtsId>RWX83@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="71be96e7-ab46-42e5-a987-5a996f82d2d9">
	  <name>George Eliot Hospital</name>
	  <address>Lewis House
College Street</address>
	  <city>Nuneaton</city>
	  <state/>
	  <country>England</country>
	  <zip>CV10 7DJ</zip>
	  <rtsId>RKB15@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="c8578bb5-29be-4a47-9dd4-8b37240fac62">
	  <name>Jessops Wing</name>
	  <address>Tree Root Walk</address>
	  <city>Sheffield</city>
	  <state/>
	  <country>England</country>
	  <zip>S10 2SF</zip>
	  <rtsId>E6F6R@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="af6de610-a69e-451e-a6cb-efc920cd6474">
	  <name>Kings College Hospital</name>
	  <address>Denmark Hill</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SE5 9RS</zip>
	</trialCentre>
	<trialCentre id="8f2421ed-b1a3-4de1-a1ff-5208a379c672">
	  <name>Stoke Mandeville Hospital</name>
	  <address>Mandeville Road</address>
	  <city>Aylesbury</city>
	  <state/>
	  <country>England</country>
	  <zip>HP21 8AL</zip>
	  <rtsId>RXQ02@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="405008d5-35ec-4a00-b1ac-11066d819ea0">
	  <name>Watford General Hospital</name>
	  <address>Vicarage Road</address>
	  <city>Watford</city>
	  <state/>
	  <country>England</country>
	  <zip>WD18 0HB</zip>
	  <rtsId>RWG02@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="0251fbd5-776d-4e41-872f-293028a1bb89">
	  <name>Gloucestershire Royal Hospital</name>
	  <address>Great Western Road</address>
	  <city>Gloucester</city>
	  <state/>
	  <country>England</country>
	  <zip>GL1 3NN</zip>
	  <rtsId>RTE03@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="25c81258-b9ce-4b78-9267-9309783f7057">
	  <name>Derriford Hospital</name>
	  <address>Derriford Road
Derriford</address>
	  <city>Plymouth</city>
	  <state/>
	  <country>England</country>
	  <zip>PL6 8DH</zip>
	  <rtsId>RH8D2@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="642888e7-d74c-4744-b599-eca52d59092f">
	  <name>Singleton Hospital</name>
	  <address>Sketty Lane
Sketty</address>
	  <city>Swansea</city>
	  <state/>
	  <country>Wales</country>
	  <zip>SA2 8QA</zip>
	  <rtsId>7A3C4@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>Participants may enter the study if ALL of the following apply:
1.	Pregnant, confirmed by presence of foetal heartbeat on either an early viability ultrasound scan performed around 7-8 weeks gestation, or on a dating ultrasound scan at ~12 weeks gestation
2.	Diagnosed with GDM in pregnancy by an oral glucose tolerance test (OGTT) per local diagnostic criteria (NICE or SIGN criteria) or by serial glucose monitoring
3.	Aged 16 years or above
4.	Primiparous or multiparous
5.	Singleton or multiple pregnancy
6.	Up to 31+6 weeks gestation at diagnosis of GDM
7.	Able to give informed consent to participate in the trial</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="16.0">16 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="60.0">60 Years</upperAgeLimit>
      <gender>Female</gender>
      <targetEnrolment>2116</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>Participants may not enter the study (i.e. may not be randomised) if ANY of the following apply:
Women with others forms of diabetes that are not GDM, including type 1 diabetes mellitus, type 2 diabetes mellitus or monogenic diabetes</exclusion>
      <recruitmentStart>2027-01-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Metabolic and endocrine, reproductive health and childbirth</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The RECOGNISED trial is a multi-centre, open-label, parallel group RCT in patients with GDM with internal pilot, embedded qualitative research and a study within a trial (SWAT).  In the RECOGNISED trial, pregnant women with GDM, who have no other forms of diabetes, will be randomised in a 1:1 ratio to monitor their blood glucose using either self monitoring of blood glucose (SMBG; usual care) or CGM until delivery.

The trial will aim to recruit 2116 participants with 1058 participants in each arm from 25 UK sites. An internal pilot will establish whether enough locations can be opened to recruitment and eligible patients can be identified, recruited and will adhere to their allocated treatment over the course of the trial to robustly answer the trial questions. The internal pilot will last for 9 months. If the progression criteria are met, the main trial recruitment will continue and patients from the internal pilot will be included in the final analysis.

Randomisation will take place before 32 weeks of pregnancy. Randomisation will be performed by an authorised member of the local research team using a centralised, computer-generated allocation sequence and secure, web-based randomisation service (https://www.sealedenvelope.com/). Participants will be randomised in a 1:1 ratio to CGM or finger prick SMBG (usual care). Randomisation will be minimised by hospital and stratified by GDM in previous pregnancy/ies (Yes/No).

Participants in the SMBG group will be told to continue monitoring their blood glucose using SMBG. Participants in the CGM group will be shown how to use the CGM system. Participants will complete questionnaires at the baseline visit and the research team will record details about them and their pregnancy. Participants in the SMBG group will additionally have a blinded CGM device fitted which they will wear for 2 weeks.

Participants will be followed up at approximately 34 weeks of pregnancy when they will complete more questionnaires and some participants will have an additional blood test to measure HbA1c if this has not been done as part of usual care. The SMBG group will wear another blinded sensor for two weeks. After the delivery of the baby(ies) and at 28 days postnatal the research team will record details about the delivery and the health of the mother and baby(ies). A final follow up will occur at 13 weeks postnatal, where participants will complete some final questionnaires and the local research team will complete a records review to record clinical and resource use information for the mother and baby(ies).

Patients will also be invited to take part in the embedded qualitative study and can optionally consent to the trial team audio-recording the interviews about their experience. Additionally, a SWAT (Study Within A Trial) will be embedded into the RECOGNISED study. The SWAT will pilot a co-developed AI recruitment video, which can be translated into other languages, at a small number of sites. Participants can optionally consent to interviews to explore the views of participants on the acceptability of the AI video.</description>
	<interventionType>Mixed</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Data sharing statement to be made available at a later date</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>e9655a8c-1dea-4901-8343-1f571e54f7fc</funderId>
      <contactId>b4a7719d-be27-4c57-80ce-3ef07d36604e</contactId>
      <contactId>2837a90d-cb93-4ea1-91aa-e27a54c84783</contactId>
      <sponsorId>c1883c03-d3be-4208-aa5d-0e428f13735f</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="b4a7719d-be27-4c57-80ce-3ef07d36604e">
    <title>Ms</title>
    <forename>Ellie</forename>
    <surname>Newbury</surname>
    <orcid/>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bristol Trials Centre, Bristol Medical School, University of Bristol, 1-5 Whiteladies Road, Clifton</address>
      <city>Bristol</city>
      <state/>
      <country>United Kingdom</country>
      <zip>BS8 1NU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)117 455 0629</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">recognised-study@bristol.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="2837a90d-cb93-4ea1-91aa-e27a54c84783">
    <title>Dr</title>
    <forename>Christy</forename>
    <surname>Burden</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Women’s Health Services
Bristol NHS Foundation Trust
Southmead Hospital</address>
      <city>Bristol</city>
      <state/>
      <country>United Kingdom</country>
      <zip>BS10 5NB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">Not provided</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">christy.burden@bristol.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="c1883c03-d3be-4208-aa5d-0e428f13735f">
    <organisation>Bristol NHS Foundation Trust</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/054vvq170</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="e9655a8c-1dea-4901-8343-1f571e54f7fc">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-10-21T10:20:40.816985759Z" version="11" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN39538766" publicIdentifierDateAssigned="2026-10-21T10:20:40.930666Z">
    <isrctn dateAssigned="2026-10-21T10:20:40.930666Z">39538766</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>Hippocrates is a research trial which aims to help us understand  how the NHS can help people who need a major operation to recover better and more quickly after the operation</title>
      <scientificTitle>Health Inequalities in PerioPerative Outcomes – CReATing and Evaluating targeted Support interventions (HIPPOCRATES): a pilot multi-arm randomised controlled trial</scientificTitle>
      <acronym>HIPPOCRATES</acronym>
      <studyHypothesis>1. Deliver a pilot randomised trial using a multi-arm methodology to evaluate three co-designed interventions in patients undergoing elective major surgery from deprived and non-deprived socioeconomic groups
2. Evaluate the implementation (feasibility, acceptability and fidelity) of these interventions using mixed methods
3. Estimate the cost-effectiveness of the three interventions evaluated during the pilot RCT
4. Selection and refinement of the most promising intervention to move forward to large scale RCT based on the mixed methods evaluation</studyHypothesis>
      <plainEnglishSummary>Background and study aim
Every year more than 1.5 million people in the UK have major surgery, and more than 1 in 7 have a serious complication afterwards. People who live in poorer areas are more likely to have complications and to recover less well. This study is testing three types of support, designed together with patients from poorer areas, to find out whether they are practical, acceptable and good value for money. The results will then inform decisions on which intervention(s) should be tested in a larger trial, either alone or in combination with each other.

Who can participate? 
Adults aged 18 or over who are on the waiting list for a major operation (not heart or brain surgery) that usually needs at least 3 nights in hospital, with surgery expected to take place in 1 to 6 months.

What does the study involve? 
Participants are put by chance into one of four groups: 
1. Help to get fitter and healthier before surgery, covering exercise, diet, mental wellbeing and long-term health conditions
2. Financial and welfare support and advice and, if needed, additional support in the form of vouchers
3. A small wearable monitor and text-message check-ins after the operation to spot problems early
4. Usual NHS care

Everyone completes short questionnaires before surgery and at 1, 6 and 12 months afterwards. Some people will be invited to talk about their experience in an interview. Information is available in the five most common languages other than English and in other formats.

What are the possible benefits and risks of participating? 
Participants may recover better, but this cannot be guaranteed. The risks are small. Exercise is prescribed by trained staff, and people at higher risk exercise only under supervision. Completing questionnaires takes some time.

Where is the study run from?
The study is coordinated by University College London (UCL), through its Comprehensive Clinical Trials Unit, and will take place at approximately 12 NHS hospitals across England (UK), with the possibility of additional sites.

When is the study starting and how long is it expected to run for? 
Recruitment is expected to run from January 2027 for a minimum of one year. Each participant is followed up for 12 months after their operation. The trial team are seeking additional funding to evaluate new interventions, so it is possible that the duration of this pilot study will be extended. Completion is in October 2029.

Who is funding the study? 
National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research (UK).

Who is the main contact? 
HIPPOCRATES trial team, cctu.hippocrates@ucl.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="f9e763b9-5fea-42fe-88bc-a5a5dab4b8cc">
	  <variable>The total number of days a patient stays alive and outside of a hospital setting</variable>
	  <method>the Days Alive and Out of Hospital at 30 days post-surgery (DOAH30)</method>
	  <timepoints>30 days post-surgery</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="cc2a6011-52d8-4df8-90ce-55635615fe81">
	  <variable>Inpatient postoperative complications (Clavien-Dindo grading)</variable>
	  <method>prospective data collection at trial location-level (research staff led)</method>
	  <timepoints>hospital discharge</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="e7fc53e5-a598-4163-b4fe-15eae5264181">
	  <variable>Postoperative hospital length of stay (LOS) until medically fit for discharge</variable>
	  <method>prospective data collection at trial location-level (research staff led)</method>
	  <timepoints>hospital discharge</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9b62a273-3474-45c1-9490-f3bc5bf42352">
	  <variable>Postoperative LOS (total on primary admission)</variable>
	  <method>prospective data collection at trial location-level (research staff led)</method>
	  <timepoints>hospital discharge</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="7d8c2ea2-dfb8-45a9-843e-16ffa00e6bcc">
	  <variable>Time between date of study recruitment/randomisation and date of surgery</variable>
	  <method>prospective data collection at trial location-level (research staff led)</method>
	  <timepoints>hospital discharge</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="1ae02003-667d-43ac-aaf4-3df651a2a9fa">
	  <variable>Health-related quality of life</variable>
	  <method>the EuroQol Five-Dimension Five-Level questionnaire (EQ-5D-5L)</method>
	  <timepoints>baseline, preoperatively, and 30 days, 6 months, and 12 months postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="ad17f4d4-e6a6-4a2c-a4c2-b8cc9d03a712">
	  <variable>Disability and functioning</variable>
	  <method>the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)</method>
	  <timepoints>baseline, preoperatively, and 6 months and 12 months postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="79b1f0ca-3831-4766-9238-1cf08d71e270">
	  <variable>Anxiety and depression symptoms</variable>
	  <method>the Hospital Anxiety and Depression Scale (HADS)</method>
	  <timepoints>baseline, preoperatively, and 30 days postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="3e351e10-b267-4cf5-aa4a-ee3d19df236e">
	  <variable>Functional capacity</variable>
	  <method>the Duke Activity Status Index (DASI)</method>
	  <timepoints>baseline and preoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="eb7e331a-c79b-4e2e-b09d-002f982cf849">
	  <variable>Healthcare resource use</variable>
	  <method>the Resource Use Measure questionnaire</method>
	  <timepoints>baseline and 6 months and 12 months postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="f7bef44f-5f66-4980-83f4-89a67988bb5a">
	  <variable>Decision regret</variable>
	  <method>the Decision Regret Scale</method>
	  <timepoints>30 days, 6 months, and 12 months postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="b6959778-cd86-42f4-a955-e2ef8145a227">
	  <variable>All-cause mortality</variable>
	  <method>linkage to NHS England Hospital Episode Statistics (HES) and/or Office for National Statistics (ONS) mortality records</method>
	  <timepoints>30 days, 90 days, and 1 year postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="67cb754c-7d30-45ed-a08e-d9e169890737">
	  <variable>Days alive and out of hospital</variable>
	  <method>linkage to NHS England HES and/or ONS mortality records</method>
	  <timepoints>30 days, 90 days, 180 days, and 1 year postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="ce1e1ea2-d25a-4858-b988-afc7c25f9820">
	  <variable>Long-term survival</variable>
	  <method>linkage to NHS England HES and/or ONS mortality records</method>
	  <timepoints>up to 10 years postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c96b3324-1aa9-44d4-a323-05b80cdea09c">
	  <variable>Time to first eating, drinking and walking following surgery,</variable>
	  <method>prospective data collection</method>
	  <timepoints>during the postoperative hospital stay</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="2f9510e9-47dc-4dff-8bcf-c2e052eb902d" approvalStatus="submitted" statusDate="2026-09-10T00:00:00.000Z">
	  <committeeName>South West – Central Bristol Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/SW/0113</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN39538766</doi>
      <eudraCTNumber/>
      <irasNumber>372779</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 74267, NIHR: 206782, 209242</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="38b67e32-694a-4bd9-a7b2-b06afc61b535" numberType="iras" canonicalSecondaryNumber="IRAS372779">372779</secondaryNumber>
	<secondaryNumber id="fb01ffc2-a4a8-41e6-8fc5-7ccd0f80308a" numberType="cpms" canonicalSecondaryNumber="CPMS74267">74267</secondaryNumber>
	<secondaryNumber id="a768e11c-3e91-4d40-ade8-22551a760b7b" numberType="nihr" canonicalSecondaryNumber="NIHR206782">206782</secondaryNumber>
	<secondaryNumber id="7656505d-0a7a-4709-a5bc-46aeb1018371" numberType="Sponsor R&amp;D ID">209242</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Supportive care</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2029-10-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="61205437-6d88-4637-8ae5-aab75654911c">
	  <name>University College London Hospitals NHS Foundation Trust</name>
	  <address>4th Floor
170 Tottenham Court Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>W1T 7HA</zip>
	</trialCentre>
	<trialCentre id="efb0135f-989e-4976-b2a1-90b714142571">
	  <name>Blackpool Victoria Hospital</name>
	  <address>Whinney Heys Road</address>
	  <city>Blackpool</city>
	  <state/>
	  <country>England</country>
	  <zip>FY3 8NR</zip>
	  <rtsId>RW5GJ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="e6b8e9c3-03c8-414f-84eb-3dfaa29adddb">
	  <name>Queen Elizabeth Hospital</name>
	  <address>Mindelsohn Way
Edgbaston</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B15 2GW</zip>
	  <rtsId>RTHH6@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="74f697b5-742b-42d4-976c-db1bdb874800">
	  <name>King's College Hospital</name>
	  <address>Denmark Hill</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SE5 9RS</zip>
	</trialCentre>
	<trialCentre id="0e8e280e-8cee-4c65-8e1b-d7b0d1808981">
	  <name>St. James' University Hospital</name>
	  <address>Beckett Street</address>
	  <city>Leeds</city>
	  <state/>
	  <country>England</country>
	  <zip>LS9 7TF</zip>
	  <rtsId>RY608@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="10f84ca1-dd4f-466b-815f-44d0ee7ae981">
	  <name>Sunderland Royal Hospital</name>
	  <address>Kayll Road</address>
	  <city>Sunderland</city>
	  <state/>
	  <country>England</country>
	  <zip>SR4 7TP</zip>
	  <rtsId>RXPWE@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="798437d6-cb8e-421b-b547-5f86926217cd">
	  <name>Derriford Hospital</name>
	  <address>Derriford Road
Derriford</address>
	  <city>Plymouth</city>
	  <state/>
	  <country>England</country>
	  <zip>PL6 8DH</zip>
	  <rtsId>RH8D2@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="f26f6b2f-3788-4daa-9ddc-1c1f8bd513f8">
	  <name>Royal Liverpool University Hospital</name>
	  <address>Prescot Street</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L7 8XP</zip>
	  <rtsId>RBN58@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="bb045dcd-1a75-4001-a4db-07c3c4fef5b0">
	  <name>Colchester General Hospital</name>
	  <address>Turner Road</address>
	  <city>Colchester</city>
	  <state/>
	  <country>England</country>
	  <zip>CO4 5JL</zip>
	</trialCentre>
	<trialCentre id="3d2ca0c7-7848-48d1-b9a3-6df715f62aaa">
	  <name>Worthing Hospital</name>
	  <address>Lyndhurst Road</address>
	  <city>Worthing</city>
	  <state/>
	  <country>England</country>
	  <zip>BN11 2DH</zip>
	  <rtsId>RDR1D@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="bd52c157-611a-4f9b-81a8-f0bf52a97ea2">
	  <name>Freeman Hospital</name>
	  <address>Freeman Road
High Heaton</address>
	  <city>Newcastle upon Tyne</city>
	  <state/>
	  <country>England</country>
	  <zip>NE7 7DN</zip>
	  <rtsId>RTD01@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="c0b90963-cdfc-40f8-87cd-5ec9953a5657">
	  <name>University College London Hospital</name>
	  <address>250 Euston Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 2PG</zip>
	  <rtsId>K2Z3D@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="b5679ae7-abd2-4c91-b64d-3232983c6c62">
	  <name>The James Cook University Hospital</name>
	  <address>Marton Road</address>
	  <city>Middlesbrough</city>
	  <state/>
	  <country>England</country>
	  <zip>TS4 3BW</zip>
	  <rtsId>RTRAT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="5bf790e8-2408-45cb-96a3-76821dc4af25">
	  <name>Bristol NHS Foundation Trust</name>
	  <address>Trust Headquarters
Marlborough Street</address>
	  <city>Bristol</city>
	  <state/>
	  <country>England</country>
	  <zip>BS1 3NU</zip>
	  <rtsId>RA7@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Age 18 years or older
2. Undergoing elective or expedited major non-cardiac surgery with an expected postoperative hospital length of stay (LOS) of 3 or more days
3. Planned date of surgery between 1 and 6 months from the time of recruitment and randomisation (based on treatment pathway and local waiting times)
4. Able to provide written informed consent
5. Able and willing to complete questionnaires (translated and alternative-format materials available)</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>420</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>Age under 18 years on the date of recruitment and randomisation</exclusion>
      <recruitmentStart>2027-01-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-01-05T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Socioeconomic inequalities in outcomes after elective or expedited major non-cardiac surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>HIPPOCRATES is a pilot platform (multi-arm, multi-stage) trial comparing three co-designed interventions with standard care. Further interventions may be added by protocol modification.

Arm A (intervention 1): Preoperative optimisation and prehabilitation. From randomisation until surgery (1–6 months), participants complete four validated screening questionnaires covering long-term conditions and health behaviours, cardiorespiratory fitness, nutritional status and psychological health. A named clinical coordinator then triages each domain to Level 1 (generic advice, e.g. leaflets, videos, surgery school), Level 2 (structured non-specialist support, e.g. health coaching, social prescribing, free access to local gyms, an exercise app and online classes, and free protein supplements) or Level 3 (specialist support from a dietitian, psychologist, exercise physiologist or relevant medical specialist).

Arm B (intervention 2): Financial navigation and support. A baseline discussion with a trained clinical staff member, followed by opt-out referral to Citizens Advice for navigation to state benefits, referral to NHS transport support and, if eligible, shopping vouchers up to the value of £200 for patients in financial crisis while benefits are processed. Regular check-ins by text, email or phone before and after surgery give participants the opportunity to opt back into support.

Arm C (intervention 3): Postoperative enhanced surveillance. A wireless wearable monitor (CheckPoint Cardio chest-worn patch and pulse oximeter) worn from leaving the operating theatre, throughout the postoperative hospital stay and for up to 48 hours after discharge, with continuous 24-hour remote monitoring. Alerts are routed through existing hospital escalation pathways (surgical team in hours; critical care outreach team out of hours). Text-message check-ins start during the inpatient stay and continue for up to 30 days after discharge.

Arm D: Standard of care at each NHS provider. Hospitals routinely offering any of the trial interventions are not eligible as trial sites.

Participants are allocated 1:1:1:1 (target 420 participants, 105 per arm). Following the screening visit and allocation of a participant identification number, the PI or delegate will enter the participant's initials, sex, age, date of consent, eligibility and other variables required for minimisation on the SealedEnvelope.com secure online system, which re-confirms eligibility and assigns the treatment arm.</description>
	<interventionType>Mixed</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>Anonymised individual participant data will be available after the main trial results are published (expected within 12 months of the end of the trial). Requests must be made in writing to UCL CCTU (cctu.hippocrates@ucl.ac.uk), must have a strong scientific or other legitimate rationale, and will be considered by the trial oversight committees and the Chief Investigator.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Available on request</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e2ccf5ce-9ed7-4a20-8c6d-d1a1a1099a8f" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-09-07T00:00:00.000Z" dateUploaded="2026-10-13T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="70e28a32-7c01-42d0-bf38-794335ce6ce6" originalFilename="49999_Protocol_v1.0_07Sep2026.pdf" downloadFilename="49999_Protocol_v1.0_07Sep2026.pdf" version="1.0" mimeType="application/pdf" length="1284628" md5sum="6853451cfab6a0ec2129f1058085be37"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>8f3a2dd3-5dca-4abf-a748-3d1fc76f1281</funderId>
      <contactId>5bed5c5f-605f-4d94-9c86-9d58b7a1914d</contactId>
      <sponsorId>02bd339b-209b-4dfb-84fa-e73e1b8289b7</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/70e28a32-7c01-42d0-bf38-794335ce6ce6/49999">
	<description>Protocol file</description>
	<name>49999_Protocol_v1.0_07Sep2026.pdf</name>
	<id>70e28a32-7c01-42d0-bf38-794335ce6ce6</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>1284628</length>
	<md5sum>6853451cfab6a0ec2129f1058085be37</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="5bed5c5f-605f-4d94-9c86-9d58b7a1914d">
    <title>Prof</title>
    <forename>S. Ramani</forename>
    <surname>Moonesinghe</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>University College London Hospitals NHS Foundation Trust
4th Floor
170 Tottenham Court Road</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1T 7HA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 02031086154</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cctu.hippocrates@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="02bd339b-209b-4dfb-84fa-e73e1b8289b7">
    <organisation>University College London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/02jx3x895</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="8f3a2dd3-5dca-4abf-a748-3d1fc76f1281">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-09-30T09:29:50.131861222Z" version="10" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN80009790" publicIdentifierDateAssigned="2026-09-30T09:45:17.973318Z">
    <isrctn dateAssigned="2026-09-30T09:45:17.973318Z">80009790</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>Investigating and improving care (education) and treatment reviews (C(E)TRs)</title>
      <scientificTitle>Optimising community C(E)TRs through understanding the experience of people with learning disability and autistic people and investigating their impact on care</scientificTitle>
      <acronym>OptiCaT</acronym>
      <studyHypothesis>1. Do C(E)TRs reduce hospital admissions (primary outcome) and duration of hospital stay in people with learning disability and/or autistic people who are at risk of psychiatric hospital admission? 
2. Do C(E)TRs improve other clinical, health and social outcomes? 
3. Are C(E)TRs cost-effective?</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Care (Education) and Treatment Reviews, or C(E)TRs, were introduced in England in 2015 to help people with a learning disability and autistic people get the right support in the community and avoid unnecessary admission to a mental health hospital. However, there is limited evidence about how well C(E)TRs work. This study aims to find out whether community C(E)TRs reduce hospital admissions and improve people’s health, wellbeing and care. 

Who can participate?
The study is for people aged 14 years or older who have a learning disability and/or are autistic, are receiving support from an NHS community mental health services, and are considered at increased risk of admission to a mental health hospital. Family members and paid carers of participants can also take part.

What does the study involve?
People with a learning disability and autistic people from different parts of England will be recruited to the study and followed-up over time. Researchers will collect information about hospital admissions, mental health, behaviour, quality of life, medication, use of health and social care services, and the care and support people receive. The information will be collected at the point of recruitment, at 6 months, and at 9 months. The information will be collected by questionnaires that a researcher will go through with the participant. The data that are collected will allow researchers to compare people who have a C(E)TR with people who do not.

What are the possible benefits and risks of participating?
People taking part may not receive a direct personal benefit. However, the information they provide may help improve C(E)TRs and the support provided to people with a learning disability and autistic people in the future.
The study is considered to be low risk. Completing questionnaires and assessments will take some time and may be tiring. Interviews may involve discussing difficult experiences, including times when community care has broken down or when hospital admission has been needed, and this could be upsetting. Participants can take a break or stop an interview if they wish, and the research team will help them access appropriate support if needed.

Where is the study run from?
The study is led by King’s College London (UK), in partnership with Queen Mary University of London and other universities and NHS organisations. Participants are being recruited through NHS services in different parts of England so that the study includes people from a range of geographical areas and communities. 

When is the study starting and how long is it expected to run for?
August 2025 to February 2028

Who is funding the study?
The study is funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research Programme (reference NIHR158490)

Who is the main contact?
Dr Rory Sheehan, opticatstudy@kcl.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="cf7f4c9f-53d7-4d55-bf9f-c10d98b49ce0">
	  <variable>Admission to psychiatric hospital</variable>
	  <method>the modified version of the Adult Service Use Schedule (AD-SUS) and also provided by the clinician</method>
	  <timepoints>baseline, 6 months, and 9 months</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome>1. Psychiatric symptoms measured using the Moss Psychiatric Assessment Schedule - Check (Moss-PAS (Check)) at baseline, 6 months, and 9 months
2. Behaviour that challenges measured using the Behaviour Problems Inventory - Short Form (BPI-S) at baseline, 6 months, and 9 months
3. Unmet care needs measured using the Camberwell Assessment of Needs for Adults with Developmental and Intellectual Disabilities - Research version (CANDID-R) at baseline, 6 months, and 9 months
4. Quality of Life measured using the 13-item WHOQOL Disabilities module (WHOQOL-DIS) at baseline, 6 months, and 9 months
5. Health-related quality of life measured using the EuroQoL Five Dimensions - Three Levels questionnaire (EQ-5D-3L) at baseline, 6 months, and 9 months
6. Service use (health and social care contacts) measured using a modified version of the Adult Service Use Schedule (AD-SUS) at baseline, 6 months, and 9 months
7. Family carer distress measured using the Kessler Psychological Distress Scale (K6) at baseline, 6 months, and 9 months
8. Family carer health-related quality of life measured using the EuroQol 5-Dimension 5-Level questionnaire at baseline, 6 months, and 9 months
9. Clinician-rated participant symptom severity measured using the Clinical Global Impression-Severity (CGI-S) Scale at baseline, 6 months, and 9 months
10. Clinician-rated participant health and social functioning measured using the Health of the Nation Outcome Scales (HoNOS) at baseline, 6 months, and 9 months
11. Clinician-rated participant exposure to restrictive practices (physical, mechanical, or chemical restraint) measured using a questionnaire created by the research team at baseline, 6 months, and 9 months
12. Psychotropic medication prescribing measured using a questionnaire created by the research team at baseline, 6 months, and 9 months</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="444d349d-37ee-402d-95a0-7d27ff568b2e" approvalStatus="approved" statusDate="2025-07-31T00:00:00.000Z">
	  <committeeName>Leeds West Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>NHSBT Newcastle Blood Donor Centre
Holland Drive</address>
	    <city>Newcastle upon Tyne</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>NE2 4NQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>25/YH/0119 </committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN80009790</doi>
      <eudraCTNumber/>
      <irasNumber>335048</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NIHR: 158490</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="a8529dce-a654-4418-b14a-ad6967352af8" numberType="iras" canonicalSecondaryNumber="IRAS335048">335048</secondaryNumber>
	<secondaryNumber id="652f8526-e929-4e33-93f9-63b1ee8dc891" numberType="nihr" canonicalSecondaryNumber="NIHR158490">158490</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Longitudinal study</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2028-02-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2a539c7d-6248-4eca-a8d4-bd1e316216e9">
	  <name>Oxleas NHS Foundation Trust</name>
	  <address>Pinewood House
Pinewood PLACE</address>
	  <city>Dartford</city>
	  <state/>
	  <country>England</country>
	  <zip>DA2 7WG</zip>
	  <rtsId>RPG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="602b96de-ba56-4011-bf7c-567d678a0f14">
	  <name>South London and Maudsley NHS Foundation Trust</name>
	  <address>Bethlem Royal Hospital
Monks Orchard Road</address>
	  <city>Beckenham</city>
	  <state/>
	  <country>England</country>
	  <zip>BR3 3BX</zip>
	  <rtsId>RV5@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="ef2b351d-157a-4e3c-af4f-dbdcac294264">
	  <name>North London NHS Foundation Trust</name>
	  <address>4th Floor, East Wing
St. Pancras Hospital
4 St. Pancras Way</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 0PE</zip>
	  <rtsId>G6V2S@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1c258490-7c22-44a9-ba03-cd45bee2e57a">
	  <name>East London NHS Foundation Trust</name>
	  <address>Robert Dolan House
9 Alie Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>E1 8DE</zip>
	  <rtsId>RWK@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="37fd0b66-7d9a-4f5e-88dc-35e37e35dcb5">
	  <name>Central and North West London NHS Foundation Trust</name>
	  <address>Trust Headquarters
350 Euston Road
Regents PLACE</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 3AX</zip>
	  <rtsId>RV3@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="486912aa-4b0e-40d6-b706-a1c383422c68">
	  <name>Lincolnshire Partnership NHS Foundation Trust Hq</name>
	  <address>NHS Foundation Trust
Carholme Court
Long Leys Road</address>
	  <city>Lincoln</city>
	  <state/>
	  <country>England</country>
	  <zip>LN1 1FS</zip>
	  <rtsId>RP7SG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="bdddd0d6-88dd-43c5-9dd6-1a217e3c8740">
	  <name>Sussex Partnership NHS Foundation Trust</name>
	  <address>Trust Hq
Swandean
Arundel Road</address>
	  <city>Worthing</city>
	  <state/>
	  <country>England</country>
	  <zip>BN13 3EP</zip>
	  <rtsId>RX2@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="a10e8854-ad70-43c6-9cc2-041361f7d1e4">
	  <name>Cornwall Partnership NHS Foundation Trust</name>
	  <address>Carew House
Beacon Technology Park
Dunmere Road</address>
	  <city>Bodmin</city>
	  <state/>
	  <country>England</country>
	  <zip>PL31 2QN</zip>
	  <rtsId>RJ8@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="6dbc9c49-1392-4f12-a11f-3726dddde28d">
	  <name>Cheshire and Wirral Partnership NHS Foundation Trust</name>
	  <address>Trust Headquarters Redesmere
The Countess of Chester Health Park
Liverpool Road</address>
	  <city>Chester</city>
	  <state/>
	  <country>England</country>
	  <zip>CH2 1BQ</zip>
	  <rtsId>RXA@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="f17dfe83-8dc6-4500-8538-670d9de4d236">
	  <name>Tees, Esk and Wear Valleys NHS Foundation Trust</name>
	  <address>Trust Headquarters
West Park Hospital
Edward Pease Way</address>
	  <city>Darlington</city>
	  <state/>
	  <country>England</country>
	  <zip>DL2 2TS</zip>
	  <rtsId>RX3@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="4021224c-d5c8-4e41-a61d-66056f79b08e">
	  <name>Hertfordshire Partnership N H S</name>
	  <address>Harper Lane
Shenley</address>
	  <city>Radlett</city>
	  <state/>
	  <country>England</country>
	  <zip>WD7 9HQ</zip>
	  <rtsId>V09887@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1578ec26-bc8f-4a04-b351-37d2459d8fd4">
	  <name>North East London NHS Foundation Trust</name>
	  <address>Goodmayes Hospital
157 Barley Lane</address>
	  <city>Ilford</city>
	  <state/>
	  <country>England</country>
	  <zip>IG3 8XJ</zip>
	  <rtsId>RAT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="c2fc0a3d-7f0c-47c5-9caf-e4e7f976b0f3">
	  <name>Surrey and Borders Partnership NHS Trust Hq</name>
	  <address>18 Mole Business Park
Randalls Road</address>
	  <city>Leatherhead</city>
	  <state/>
	  <country>England</country>
	  <zip>KT22 7AD</zip>
	  <rtsId>RXXHQ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="603a91fb-8c7f-49f7-94eb-d93d61828675">
	  <name>South West London and St George's Mental Health NHS Trust</name>
	  <address>Springfield Hospital
61 Glenburnie Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SW17 7DJ</zip>
	  <rtsId>RQY@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Children/adolescents (aged between 14 and 17 years, inclusive) or adults (≥18 years) with a clinical diagnosis of learning disability (of any degree) or autism (diagnosis based on service records, expected to conform to ICD-10 chapter F7- criteria for learning disability or ICD-10 F84 criteria for autism)  
2. Under the care of a community mental health service (e.g., Child and Adolescent Mental Health Services [CAMHS], Community Learning Disability Team [CLDT], Community Mental Health Team [CMHT])  in a participating Trust
3. Rated as red or amber on the Dynamic Support Register (DSR)
4. Provide informed consent to taking part or, where an adult lacks capacity to consent to participate, a personal or nominated consultee has signed a declaration form or, in the case of children/adolescents (&lt;18 years), a parent/guardian has signed a consent form</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="14.0">14 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="99.0">99 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. No clinically-confirmed diagnosis of learning disability or autism 
2. Not on the Dynamic Support Register
3. Currently admitted to a psychiatric hospital
4. Does not provide informed consent or, where an adult lacks capacity, there is no consultee declaration or, in the case of children/adolescents (&lt;18 years) a parent/guardian has not signed a consent form</exclusion>
      <recruitmentStart>2025-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intellectual (learning) disability or autism spectrum disorder</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is an observational prospective cohort study recruiting people aged 14 years and over with a learning disability and/or autism who are considered at increased risk of psychiatric hospital admission (as identified by being rated red or amber on the Dynamic Support Register [DSR]). Participants will be recruited through NHS community mental health services across diverse areas of England. Family or paid carers may also take part.

Participants will complete assessments at the start of the study and again at 6 and 9 months. Information will be collected from participants, carers and clinicians about psychiatric hospital admissions, mental health and behaviour, quality of life, unmet needs, use of health and social care services, medication and restrictive practices. Assessments can be completed face-to-face, by telephone or online. We would expect some people to receive a C(E)TR during follow-up and others will not. 

The main outcome is admission to psychiatric hospital during follow-up. Secondary outcomes include psychiatric symptoms (measured by the Moss-PAS Check), behaviour that challenges (Behaviour Problems Inventory - Short form), unmet need (CANDID-R), quality of life (WHOQOL-DIS), health-related quality of life (EuroQoL Five Dimensions), service use (contacts with health and social care using a modified version of the Adult Service Use Schedule), all of which will be completed by the participant with learning disability or autism. Family carers who are enrolled will complete measures of family carer distress (Kessler Psychological Distress Scale), and carer health-related quality of live (EQ-5D-5L). Clinicians providing care to recruited participants will provide information on participant symptom severity (using the Clinical Global Impression-Severity scale), participant health and social functioning (measured with Health of the Nation Outcome Scale, HoNOS), use of restrictive practices (i.e. Mental Health Act, Deprivation of Liberty Safeguards), psychotropic medication, and whether a C(E)TR was conducted. 

The main outcome will be psychiatric hospital admission during follow-up. Outcomes will be compared between participants who receive a C(E)TR and those who do not, to investigate whether C(E)TRs are associated with a reduced likelihood of hospital admission and better health and care outcomes.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>7ec7713b-595d-402c-8112-c08062629892</funderId>
      <contactId>51829bab-ef10-4763-8132-5e6692178f42</contactId>
      <sponsorId>1c435748-e516-4e3f-a3f5-a034fa55a259</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="51829bab-ef10-4763-8132-5e6692178f42">
    <title>Dr</title>
    <forename>Rory</forename>
    <surname>Sheehan</surname>
    <orcid>https://orcid.org/0000-0002-4164-9661</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute of Psychiatry, Psychology &amp; Neuroscience
King's College London</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SE5 8AF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7848 0002</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rory.sheehan@kcl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="1c435748-e516-4e3f-a3f5-a034fa55a259">
    <organisation>South London and Maudsley NHS Foundation Trust</organisation>
    <sponsorType/>
    <rorId>https://ror.org/015803449</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="7ec7713b-595d-402c-8112-c08062629892">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-09-03T13:11:08.751155596Z" version="13" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN43999465" publicIdentifierDateAssigned="2026-09-04T09:58:27.871063Z">
    <isrctn dateAssigned="2026-09-04T09:58:27.871063Z">43999465</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study testing local fresh food initiatives within social housing communities</title>
      <scientificTitle>A three-arm clustered randomised-controlled superiority trial to compare the effect of a weekly community mobile greengrocer stop (with and without provision of monetary vouchers) versus comparator on fruit and vegetable intake in social housing communities in Liverpool, UK</scientificTitle>
      <acronym>SCHOUSE</acronym>
      <studyHypothesis>To compare differences in fruit and vegetable intake after 26 weeks between:
A.	A comparison group who receive signposting to support and community food initiatives (Comparator), and a group who additionally receive a new weekly mobile greengrocer stop in their neighbourhood (Intervention 1) for 26 weeks, and
B.	Intervention 1 and a group who receive provision of weekly vouchers for use at the greengrocer in addition to a new weekly mobile greengrocer stop in their neighbourhood (Intervention 2) for 26 weeks</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Eating a healthy diet can be difficult. Most people in the UK struggle to eat the five recommended portions of fruit and vegetables per day. Not eating enough fruit and vegetables can increase the risk of health problems related to a low-quality diet. Because of this, it is important to understand the barriers people face to eating enough fruit and vegetables. 

In many communities, it is hard to get to shops and food outlets that sell fruit and vegetables at an affordable price. These issues of access and affordability can create significant barriers to eating a diet that promotes good health. In the UK, people living in social housing are particularly vulnerable to these barriers and the health risks that can result from them. This may be because of the food environment of the community they live in or additional challenges or disadvantages they already face. At present, there is little evidence on what can be done to improve access to and affordability of fruit and vegetables to support people to improve their diet when they live in social housing. 

Our clustered randomised control trial addresses this gap in evidence, by investigating what happens to people's diet and wellbeing when you introduce a new mobile greengrocer service to their area and what further impact providing vouchers to spend at the mobile greengrocer might have.

Who can participate?
Adults living in one of our 12 study areas in Liverpool and living in social housing provided by Onward, Riverside, or Torus. They must be 18 years or older, the person responsible for getting food for their household, and not currently in receipt of Rose vouchers from the Alexandra Rose Charity.

What does the study involve?
We will randomly allocate our 12 study areas to one of three groups. Participants in an area will receive new initiatives based on which group their area was allocated to for the duration of the 6-month trial. 

Participants from areas in Group 1 will receive monthly, digital bulletins from their housing provider, outlining local opportunities for support, upcoming events, and community-based food initiatives. 

Participants from areas in Group 2 will receive monthly bulletins, like participants in Group 1, but they will also receive the opportunity to shop at a new mobile greengrocer service within 1km of where they live. The mobile greengrocer will visit their area at the same time every week for 6-months and will sell fresh fruit and vegetables to anyone in the community who would like to shop there. 

Participants from areas in Group 3 will receive monthly bulletins and the opportunity to shop at a new mobile greengrocer service within 1km of where they live, like participants in Group 2. In addition to this, they will also receive vouchers to spend on fruit and vegetables at the mobile greengrocer each week. The participants will receive these vouchers for 6-months.  

Participants in all areas will complete a questionnaire and three online 24-hour food diaries at the beginning, middle, and end of the trial. Our main outcome of interest is fruit and vegetable intake. We want to see if (i) introducing a weekly mobile greengrocer stop to a local area supports people to increase their fruit and vegetable intake, and (ii) pairing this introduction with provision of vouchers to spend at the new service supports people to increase their fruit and vegetable intake even more than introducing the new service alone. We will also explore other outcomes that might help to understand how introducing this new service and voucher provision may work, for example, mental health and wellbeing, sense of community and social support, and barriers to doing food shopping and accessing fresh fruit and vegetables. 

What are the possible benefits and risks of participating?
People who take part will help support the trial's aim to develop an understanding of how community-based approaches to improve the access and affordability of fresh food can impact people living in social housing. By actively engaging in the new offers delivered in the trial, participants will likely improve the chances that their areas continue to be supported by these offers in the longer term. Participants who complete the trial questionnaires and food diaries across the course of trial will receive retail vouchers as compensation for their time. While there very few risks in taking part, some participants may find it uncomfortable to answer questions about their experiences and challenges around getting food, finances, health, and wellbeing.

Where is the study run from?
The trial is mainly being delivered by researchers at the University of Liverpool, UK, with support from researchers at the University of Cambridge, UK. We are also collaborating with three housing associations (Onward Homes, Riverside, and Torus) who together manage the majority of social housing properties in Liverpool. 

When is the study starting and how long is it expected to run for?
The trial is starting on Monday 7th September 2026 and is expected to be complete by the end of August 2027.

Who is funding the study?
The trial is supported by the UK Research and Innovation (UKRI) Strategic Theme on Creating Opportunities, Improving Outcomes, in partnership with UKRI’s Global Food Security programme (UKRI GFS), BBSRC, AHRC, ESRC, MRC, NERC and Innovate UK.

Who is the main contact?
Dr Courtney Neal, courtney.neal@liverpool.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="87cb0145-442a-49f8-81d7-52f83a3255c0">
	  <variable>Average daily fruit and vegetable intake (g) at endpoint</variable>
	  <method>3 x 24h dietary recalls via Intake24</method>
	  <timepoints>baseline and week 22</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="beb6ac2b-25e8-4b6d-838c-d6492042356a">
	  <variable>Average daily fruit and vegetable intake (g) at midpoint</variable>
	  <method>3 x 24h dietary recalls via Intake24</method>
	  <timepoints>baseline and week 11</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="98c45558-2a2f-44c3-bd53-4fa56e5bf4cf">
	  <variable>Average daily portions of fruit and vegetables consumed</variable>
	  <method>3 x 24h dietary recalls via Intake24</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="3c6047b5-902b-4d67-9255-e683b13dd15a">
	  <variable>Average daily intake of energy (kcal)</variable>
	  <method>3 x 24h dietary recalls via Intake24</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="b96bb432-e66a-45cd-8248-17ddb493e6d7">
	  <variable>Average daily intake of carbohydrates (g)</variable>
	  <method>3 x 24h dietary recalls via Intake24</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="4bad93a3-6b04-4e27-948a-b36063554bfa">
	  <variable>Average daily intake of protein (g)</variable>
	  <method>3 x 24h dietary recalls via Intake24</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="06c326c5-ff10-4649-836c-79e79b769099">
	  <variable>Average daily intake of fat (g)</variable>
	  <method>3 x 24h dietary recalls via Intake24</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="db013dc0-7df1-4180-b8cb-309442a20054">
	  <variable>Average daily intake of AOAC fibre (g)</variable>
	  <method>3 x 24h dietary recalls via Intake24</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="5d6b393e-55f8-459b-ab73-121c127c8138">
	  <variable>Daily portions of fruit and vegetables consumed by eldest child in household</variable>
	  <method>a parent-reported food frequency question in questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="bfbb4db5-6c45-4a80-8a2a-e9927961bf80">
	  <variable>Food insecurity status</variable>
	  <method>U.S. Adult Food Security Module (10-items) with a 30-day reference period</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="ca87d351-4794-4ab0-94ef-f3c83eff2fe4">
	  <variable>Use of emergency food support</variable>
	  <method>a self-reported frequency question in questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="f6562c74-ecb9-498f-bd9b-dab28f290b3f">
	  <variable>Use of community food projects</variable>
	  <method>a self-reported frequency question in questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="12446959-1103-4e48-a125-f46cf4ac034a">
	  <variable>Barriers to buying, cooking and eating fresh fruit and vegetables</variable>
	  <method>a self-reported question in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="498fff36-49ca-424e-b243-68a3f29222e1">
	  <variable>Household weekly spend on fresh fruit and vegetables</variable>
	  <method>a self-reported question in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="1b6b7a67-0adc-46cf-a9c1-4b9654919683">
	  <variable>Frequency of Queen of Greens use at a stop &lt;1km from home address in last three months</variable>
	  <method>a self-reported question in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="16eb856b-a6dd-4cdb-a57e-39efa5ef24c6">
	  <variable>Frequency of Queen of Greens use at a stop &gt;1km from home address in last three months</variable>
	  <method>a self-reported question in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="2ce098d5-a9de-4a21-b81e-e0a88e0fb7b5">
	  <variable>Self-efficacy in affording the fruit and vegetables needed for their household to eat a healthy diet</variable>
	  <method>a self-reported question in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="b82eefdf-45ec-4673-8b9c-35fa4b94648d">
	  <variable>Liking of eating fresh fruit</variable>
	  <method>a self-reported, VAS question in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="8a40dbd1-9c01-4f43-88d2-7691899cdde0">
	  <variable>Liking of eating fresh vegetables</variable>
	  <method>a self-reported, VAS question in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c5a292ec-d552-489c-9f76-a0b4302c7cb8">
	  <variable>Negative emotional state</variable>
	  <method>Depression, Anxiety and Stress Scale - 21 items (DASS-21) in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="e9ff43f1-9edf-4856-b95a-5997de74564d">
	  <variable>Severity of depression symptoms</variable>
	  <method>the depression sub-scale of DASS-21 in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="8502ce3a-3006-444c-bc59-cd096654579e">
	  <variable>Severity of anxiety symptoms</variable>
	  <method>the anxiety sub-scale of DASS-21 in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="a436ff85-a9ac-4264-a407-c32a1da63ec9">
	  <variable>Severity of stress symptoms</variable>
	  <method>the stress sub-scale of DASS-21 in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="d755c5e1-4498-4271-a2ac-a5d495daaff0">
	  <variable>Feelings of loneliness</variable>
	  <method>the three-item UCLA loneliness scale and a direct measure of loneliness (recommended by the Office for National Statistics) in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c4dd2a20-26fa-444f-866a-a5f2162d8108">
	  <variable>Level of social support</variable>
	  <method>the Oslo Social Support Scale (OSSS) in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="05d396b1-39bc-4f05-b70c-c5f65f7fa23e">
	  <variable>Sense of community</variable>
	  <method>the Brief Sense of Community Scale (BSCS) in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="90a978ec-4d57-4c63-a178-b6d51376ae5a">
	  <variable>Satisfaction with housing provider</variable>
	  <method>three items from the Tenant Satisfaction Measures (TSM; overall satisfaction, feeling the housing provider listens to them and acts on their needs, and  being satisfied that housing provider positively contributes to their neighbourhood)</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="a9338c06-33eb-4c0a-97e1-e57f57d4f2ac">
	  <variable>Support service use</variable>
	  <method>a self-reported question in the questionnaire</method>
	  <timepoints>baseline and week 22</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9656964d-f9d7-4b19-a52c-fa3ef04d1021">
	  <variable>Daily portions of fruit and vegetables</variable>
	  <method>a self-reported food frequency question in the questionnaire</method>
	  <timepoints>baseline, week 11, and week 22</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="df5593d5-7fe8-45a6-906a-89a42839aceb" approvalStatus="approved" statusDate="2026-08-25T00:00:00.000Z">
	  <committeeName>University of Liverpool Central University Research Ethics Committee C</committeeName>
	  <contactDetails>
	    <address>Foundation Building
University of Liverpool</address>
	    <city>Liverpool</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>L69 7ZX</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>18413</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43999465</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber/>
      <secondaryNumbers/>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Cluster</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2027-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="70eb599d-8c61-4567-999d-d3f40d1e45d4">
	  <name>University of Liverpool</name>
	  <address>Department of Public Health, Policy and Systems
Institute of Population Health
University of Liverpool
Brownlow Hill</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L69 3GB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>true</healthyVolunteersAllowed>
      <inclusion>1. Aged 18 years old or over
2. Living in one of the 12 clusters
3. Live in a property managed by Onward Homes, Riverside or Torus
4. Be the primary food procurer for their household</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="125.0">125 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>360</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Currently in receipt of Rose vouchers provided by the Alexandra Rose Charity</exclusion>
      <recruitmentStart>2026-09-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-03-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fruit and vegetable intake of people living in social housing</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>As we are conducting a clustered randomised controlled trial, we will randomise at the cluster level. In the present trial, each of our 12 trial sites is a cluster. Thus, participants will be allocated to groups depending on the trial site that they live in. 

We will randomise the 12 sites to the three intervention arms in blocks of four using the randomizr package in RStudio. Each of the four blocks will correspond to the four waves of trial rollout. The sites in the first block (as determined by the order of the randomisation list) will become the sites in the first wave, and so forth for the following blocks and waves. 

Comparator (Signposting)
The comparator condition for the trial is similar to “usual care”. It is typical for housing associations, through direct communication with dedicated housing officers or health and wellbeing staff, to provide signposting to their tenants about community food initiatives they can access. If required, they may provide referrals for specific projects (i.e., food bank referrals). They also provide signposting to welfare and benefits advice, debt support and other forms of financial support via newsletters and social media. During the trial, partner housing associations will proactively provide this information to all participants (who are also their customers) every four weeks in the form of bulletins via email or WhatsApp. When participants sign up for the trial, they will consent to receive this information.

The bulletins will be provided to all participants in the study for 26 weeks. However, participants in the Comparator arm will not receive any other interventions beyond the bulletins. The research team will contact participants in this arm on the Monday before the trial begins to inform them which arm their site is in and what to expect.

 Intervention 1 (Signposting + Mobile greengrocer)
The Queen of Greens is a mobile greengrocer service running a timetable of weekly stops across Liverpool and Knowsley in the North West of England. It sells fresh fruit and vegetables, purchased fresh from the wholesaler, from converted buses/vans which double up as a mobile shops that customers can get on board to do their shopping. Anyone can shop at the Queen of Greens and they accept Healthy Start vouchers and Alexandra Rose vouchers at all of their stops. 

In addition to receiving the bulletins outlined above, the Queen of Greens bus will begin making weekly stops in sites randomised to Intervention 1. The new stop will be within 1 km of participants' homes. In the first week of the trial, participants will be encouraged to visit the Queen of Greens bus to receive a free tote bag. Participants who are unable to collect the tote bag from the bus in this first week will have the tote bag delivered to their home address. To encourage repeat shopping on the bus, each tote bag will contain a stamp card. Each time a participant shops on the bus in the following weeks and brings their tote bag to put carry their shopping in, they will receive a stamp on their stamp card from the bus' driver after they have made their purchase. They will be able to collect a maximum of one stamp per week, up to a maximum of four stamps. Once they have filled their stamp card, they will receive a monetary voucher to spend on the bus the following week (with an approximate value of up to £5). Vouchers must be spent before Week 8 of the trial, to minimise the impact that the spending of the voucher has on midpoint dietary measures. 

The bus will be at each stop for 45 min to 1 h per week in each site. With the exception of a two week break over the Christmas and New Year period when the wholesaler closes, the Queens of Greens bus will stop at the same time every week for 26 weeks as part of the trial. It will be at the Queen of Greens' discretion as to whether they continue these stops after the trial concludes.  

On the Monday before the trial wave begins, the research team will contact participants to tell them about the new Queen of Green stop and provide information about the Queen of Greens and the tote bag/stamp card incentive. Participants will also be invited to follow the Queen of Greens on social media to receive updates on any changes to timetables or schedules. In the bulletin from their housing association, participants will receive a reminder of the date and time the Queen of Greens will be stopping. 

In summary, the Queen of Greens mobile greengrocer will:
•	Stop at a regular time and place for 45-60 min each week in intervention site locations,
•	Enable customers to buy fruit and vegetables on the bus priced in 50p increments, 
•	Not require membership or regular use,
•	Make pricing clear per each type of item,
•	Keep customers up to date via their social media on timetable changes,
•	Take customer preferences and requests into account,
•	Manage the queue so that the bus is not too crowded with customers (i.e., only 3 people on the bus at a time), 
•	Occassionally provide bundles of free, fresh herbs for customers, and
•	Occasionally provide free recipe cards for customers.

Intervention 2 (Signposting + Mobile greengrocer + Fruit and vegetable vouchers)
Alexandra Rose Charity is a charity which provides vouchers (Rose vouchers) to purchase fresh fruit and vegetables from market traders. In addition to receiving everything in Intervention 1 (bulletins and new weekly Queen of Greens stop in their area), participants in sites randomised to Intervention 2 will receive Rose vouchers to purchase fresh fruit and vegetables at the Queen of Greens. 

Participants will receive one batch of four bundles of vouchers by postal delivery every four weeks (one bundle per week) for the duration of the trial. Over the 26 week trial, participants will receive a total of 7 batches – 6 deliveries with 4 bundles (24 weeks of vouchers) and 1 delivery with 2 bundles (2 weeks of vouchers). Each bundle will include a flyer/note indicating when the participant can expect their next bundle of vouchers. Whether Rose vouchers are hand-delivered to a participant’s address or sent via the postal system depends on the approach their housing association chooses. 

We will encourage weekly use, but participants will have at least four weeks to use the vouchers they receive in a delivery. Each participant will receive £6 of Rose vouchers per week, plus an additional £2 for each additional member of their household; thus, the weekly value of vouchers each participant receives will vary by their household size. We will assess household size using the number of children and adults participants report being “usually” part of their household in the baseline questionnaire (“usually” is defined as staying with them for 2 or more nights per week).  We will not verify household size and composition with the housing associations, as we expect participants to respond honestly to these questions, given their knowledge of the housing associations' involvement in the trial. Researchers will be responsible for registering participants on Alexandra Rose Charity's system, but housing association staff will be responsible for distributing Rose vouchers to participants who due to receive Intervention 2 and who are also their customers. 

On the Monday before the trial wave begins, the research team will contact participants to inform them that they will receive vouchers to spend at Queen of Greens for the duration of the trial and explain how the distribution and redemption of the vouchers will work.
 
If participants indicate that they no longer want to participate in the trial, they will no longer receive vouchers. Otherwise, vouchers will continue to be sent to participants, even if (i) there is evidence that participants are not using them and/or (ii) participants do not complete a study midpoint or endpoint questionnaire or dietary recall. 

In summary, Rose vouchers:
•	Can only be redeemed on the Queen of Greens mobile greengrocer in Liverpool and the surrounding areas (they are not accepted elsewhere),
•	Should only be spent by the household to which they are issued,
•	Are paper vouchers that are tracked; if lost and not spent, can be voided, and new vouchers can be issued,
•	Are only available in £1 denominations and the whole £1 must be redeemed at once (at the Queen of Greens, products are priced in multiples of 50p, so a participant can spend the full value of each voucher),
•	Have a ‘use by’ date, which is roughly one month after the voucher is issued (while this is not strictly enforced, it is in place to encourage regular spending),
•	Are scanned ‘out’ by the issuing authority (e.g., housing associations) and scanned ‘in’ by the retailer on use (e.g., Queen of Greens), enabling voucher use to be tracked and retailers to claim payment for the vouchers received from Alexandra Rose.

------- A note on timings
The Queen of Greens are unable to operate over the Christmas and New Year period (approximately Monday 21st December 2026 - Monday 4th January 2027) as there wholesale supplier closes for this duration. Further, there is likely to be a significant reduction in staffing capacity from the housing associations during this period which will significantly hinder trial delivery.  For any sites in trial waves which include this period, we will treat this two-week period as a pause in the trial in all sites, regardless of allocation. Thus, we will not distribute bulletins in this period, nor will the Queen of Greens visit sites allocated to Intervention 1 or 2. In sites which are affected by this pause, we will extend the trial by two weeks and treat the pause in intervention delivery as a pause in the trial timeline (i.e., midpoint and endpoint data collection will also be pushed back by two weeks).  However, to minimise harm that may result from an abrupt stop to Rose vouchers provision, we will provide any participants receiving  Rose vouchers with two weeks' worth of vouchers to spend the week before the break in Queen of Greens' provision along with clear guidance on when they can be spent before and after the break.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The anonymised datasets generated during and/or analysed during the current study will be stored indefinitely in a publicly available repository, the University of Liverpool's Data Catalogue (https://datacat.liverpool.ac.uk/), after an embargo period from the date of data collection to allow for the publication of research findings. Access to the data will be able to be requested from the study Principal Investigator. Anonymised data from questionnaires and 24 h dietary recalls will be available following an embargo period to allow for publication of the research findings. We expect this will be approximately 1 year following the completion of data collection. Explicit consent will be obtained from participants to enable to the public sharing of their anonymised data.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Stored in publicly available repository</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0b52b26e-6214-42c5-ae6b-62cb47a5ef40" outputType="otherfiles" artefactType="LocalFile" dateCreated="2026-08-04T00:00:00.000Z" dateUploaded="2026-09-01T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="1f19a5f7-e9b0-49a6-9535-3e5367b35648" originalFilename="50184 Consent_SCHOUSE Trial v5 04Aug2026.pdf" downloadFilename="50184 Consent_SCHOUSE Trial v5 04Aug2026.pdf" version="5" mimeType="application/pdf" length="117441" md5sum="9aa14e964e174d4be2ee1ede178923be"/>
	<description>Consent form</description>
	<productionNotes/>
      </output>
      <output id="21e93a56-d22e-4909-8c08-6fbb74d06d29" outputType="pis" artefactType="LocalFile" dateCreated="2026-08-04T00:00:00.000Z" dateUploaded="2026-09-01T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="941a48c6-928f-4cbd-b968-2d802e34b659" originalFilename="50184 PIS_SCHOUSE Trial v7 04Aug2026.pdf" downloadFilename="50184 PIS_SCHOUSE Trial v7 04Aug2026.pdf" version="7" mimeType="application/pdf" length="459646" md5sum="509f98678b835e3a6323bde3d46c7c0c"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="710e8e75-4861-4005-b3f3-ed156bace5fa" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-08-28T00:00:00.000Z" dateUploaded="2026-09-01T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="7ea5492b-5a27-4f56-9649-590c6c733cb6" originalFilename="50184 Protocol_SCHOUSE Trial v2 28Aug2026.pdf" downloadFilename="50184 Protocol_SCHOUSE Trial v2 28Aug2026.pdf" version="2" mimeType="application/pdf" length="1249911" md5sum="872b651a245f54a650915c731089a29e"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>b208a79c-52ee-40db-bebf-6ab067711426</funderId>
      <contactId>533e163f-c39e-43e9-81b5-9285dd977e55</contactId>
      <contactId>743ec8cd-cc72-4709-b855-08ea2757a952</contactId>
      <sponsorId>3bd2a8b5-d6b2-461d-9ddc-98f3c0fd1515</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/1f19a5f7-e9b0-49a6-9535-3e5367b35648/50184">
	<description>Consent form</description>
	<name>50184 Consent_SCHOUSE Trial v5 04Aug2026.pdf</name>
	<id>1f19a5f7-e9b0-49a6-9535-3e5367b35648</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>117441</length>
	<md5sum>9aa14e964e174d4be2ee1ede178923be</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/941a48c6-928f-4cbd-b968-2d802e34b659/50184">
	<description>Participant information sheet</description>
	<name>50184 PIS_SCHOUSE Trial v7 04Aug2026.pdf</name>
	<id>941a48c6-928f-4cbd-b968-2d802e34b659</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>459646</length>
	<md5sum>509f98678b835e3a6323bde3d46c7c0c</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/7ea5492b-5a27-4f56-9649-590c6c733cb6/50184">
	<description>Protocol file</description>
	<name>50184 Protocol_SCHOUSE Trial v2 28Aug2026.pdf</name>
	<id>7ea5492b-5a27-4f56-9649-590c6c733cb6</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>1249911</length>
	<md5sum>872b651a245f54a650915c731089a29e</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="533e163f-c39e-43e9-81b5-9285dd977e55">
    <title>Dr</title>
    <forename>Rachel</forename>
    <surname>Loopstra</surname>
    <orcid>https://orcid.org/0000-0002-7541-6209</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Public Health, Policy and Systems
University of Liverpool</address>
      <city>Liverpool</city>
      <state/>
      <country>United Kingdom</country>
      <zip>L69 3GB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 7345 442688</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rachel.loopstra@liverpool.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="743ec8cd-cc72-4709-b855-08ea2757a952">
    <title>Dr</title>
    <forename>Courtney</forename>
    <surname>Neal</surname>
    <orcid>https://orcid.org/0000-0001-5507-4849</orcid>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Public Health, Policy and Systems
University of Liverpool</address>
      <city>Liverpool</city>
      <state/>
      <country>United Kingdom</country>
      <zip>L69 3GB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 7345 442688</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">courtney.neal@liverpool.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="3bd2a8b5-d6b2-461d-9ddc-98f3c0fd1515">
    <organisation>University of Liverpool</organisation>
    <sponsorType/>
    <rorId>https://ror.org/04xs57h96</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="b208a79c-52ee-40db-bebf-6ab067711426">
    <name>UK Research and Innovation</name>
    <fundRef>http://dx.doi.org/10.13039/100014013</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-07-27T15:49:07.367663806Z" version="15" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN30583116" publicIdentifierDateAssigned="2026-07-27T15:49:07.493213Z">
    <isrctn dateAssigned="2026-07-27T15:49:07.493213Z">30583116</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>How can we improve care for patients recovering from acute pancreatitis following discharge from hospital?</title>
      <scientificTitle>oPtimising post-dischArge care pathways after acute paNcreatitis: evaluatiOn of health seRvice utilisAtion, outcoMes</scientificTitle>
      <acronym>PANORAMA</acronym>
      <studyHypothesis>1.	Develop conceptual framework for a ‘gold-standard’ post-hospital discharge pathway (WP1)
2.	Explore patient experience of post-hospital discharge care (WP2)
3.	Explore clinician approaches to post-discharge care (WP3)
4.	Describe real-world pathways experienced by patients after hospital discharge (WP4)
5.	Identify groups at highest risk of use of health care services (WP2&amp;4)
6.	Co-produce interventions for post-discharge care pathways (WP5)</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Acute pancreatitis is a common condition that causes inflammation of the pancreas and leads to thousands of hospital admissions in the UK each year. Although most people recover enough to leave hospital, many continue to experience health problems after discharge. These can include difficulties with digestion, problems controlling blood sugar, anxiety, depression, and ongoing pain. Some people also return to hospital after they have been discharged.

At present, there is no standard approach to follow-up care after acute pancreatitis in the UK. The PANORAMA study aims to understand what support people need after leaving hospital, how current care pathways are working, and how care could be improved. The researchers also want to identify which patients are most likely to need additional support or further healthcare after discharge. Findings from the study will be used to develop recommendations for future care pathways.

Who can participate?
Different parts of the study involve different groups of people:
1. People aged 16 years or over who have experienced acute pancreatitis and received care through the NHS
2. Family members or carers of people who have experienced acute pancreatitis
3. Healthcare professionals involved in caring for patients with acute pancreatitis, including hospital doctors, specialist nurses, allied health professionals and GPs
4. Patients currently in hospital with acute pancreatitis who are due to be discharged and are able to give informed consent

The study is recruiting participants from across the United Kingdom.

What does the study involve?
The study is made up of five linked work packages (WP).

In WP1, patients, carers and healthcare professionals will be invited to complete a survey about their experiences and views of care after discharge from hospital.

In WP2, some patients and carers will be invited to take part in a virtual interview lasting up to 1 hour. Participants will discuss their experiences after leaving hospital and describe what they think could improve care.

In WP3, healthcare professionals will take part in similar interviews to explore their experiences of supporting patients after acute pancreatitis and their views on how care could be improved.

In WP4, patients who are about to be discharged from hospital after acute pancreatitis will be asked to complete questionnaires about their quality of life, mental health, digestive health and healthcare use. These questionnaires will be completed at discharge and then again after 7 days, 28 days, 3 months and 6 months. Each questionnaire session may take up to 30 minutes.

In WP5, selected patients, carers and healthcare professionals will be invited to attend a workshop to discuss the study findings and help develop recommendations for improving care after acute pancreatitis.

What are the possible benefits and risks of participating?
Participants may not receive any direct medical benefit from taking part. However, their experiences and opinions could help researchers understand how care after acute pancreatitis can be improved. The findings may help shape future services and support for patients recovering from this condition.

The risks of participation are expected to be low. Some people may find it upsetting to discuss their experiences of illness during interviews. If a participant becomes distressed, the interview can be paused or stopped, and information about support services can be provided. Participants in the questionnaire study who report signs of severe mental distress or risk of self-harm will be advised to seek help from NHS 111 or their GP.

Where is the study run from?
The study is sponsored and led by the University of Birmingham and is being conducted in collaboration with NHS hospitals across England and Scotland. Participant data will be managed through secure systems hosted by the University of Birmingham.

When is the study starting and how long is it expected to run for?
July 2026 to September 2027.

Who is funding the study?
The study is funded by the National Institute for Health and Care Research (NIHR).

Who is the main contact?
Dr Michala Pettitt
panorama-study@contacts.bham.ac.uk&gt;</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="c68d1552-ac86-45e0-8889-4c7f49eccbd9">
	  <variable>WP1: Identification of the opportunities that exist to improve care after discharge from hospital following acute pancreatitis</variable>
	  <method>survey of stakeholders to identify the key features and characteristics that define a ‘good’ follow-up pathway for patients with AP.  Qualitative content analysis using a thematic approach</method>
	  <timepoints>until saturation is reached (40 patients/ carers, 40 clinicians)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="31ae84f8-d8ea-44ea-83c0-92070d005ca7">
	  <variable>WP2: Commentary describing the experiences of participants (patients and their carers) following discharge from hospital with acute pancreatitis</variable>
	  <method>purposive selection of candidates completing an EoI to maximise sampling across collected descriptors (sex, ethnicity, aetiology, region), followed by semi-structure interviews (informed by analysis of WP1) and qualitative thematic analysis</method>
	  <timepoints>Following analysis of WP1 to run concurrently with WP3 and WP4</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9f2090b3-51d2-4521-a715-ee15b07c36dd">
	  <variable>WP3: Commentary describing the experiences of NHS clinicians with responsibilities for the care of patients with AP</variable>
	  <method>purposive selection of candidates completing an EoI to maximise sampling across collected descriptors (sex, ethnicity, aetiology, region), followed by semi-structure interviews (informed by analysis of WP1) and qualitative thematic analysis</method>
	  <timepoints>following analysis of WP1 to run concurrently with WP2 and WP4</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="48caaa50-70d5-4f3b-803e-0477c4d80831">
	  <variable>WP4: Patient demographics, Patient co-morbidities, Prior diagnosis of mental health issues, Disease aetiology and inpatient treatment, Clinician planned follow-up on discharge</variable>
	  <method>patient records</method>
	  <timepoints>baseline</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="6edd65e5-4c6b-47f2-a7d1-a7182fb44c4c">
	  <variable>WP4: Alcohol usage</variable>
	  <method>AUDIT-C PROM</method>
	  <timepoints>baseline</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="10e9f88a-3aa5-4cca-8148-f9b89cafe7e8">
	  <variable>WP4: Patient quality of life</variable>
	  <method>EQ-5D-5L PROM</method>
	  <timepoints>discharge, 7 days, 30 days, 3 months, 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="e42cc58d-6c83-44c2-886d-7f495e6e63d7">
	  <variable>WP4: Patient anxiety</variable>
	  <method>GAD-7 PROM</method>
	  <timepoints>discharge, 7 days, 30 days, 3 months, 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="51e4e232-fb01-4716-a9a1-d29cc8c63d16">
	  <variable>WP4: Patient depression</variable>
	  <method>PHQ-9 PROM</method>
	  <timepoints>discharge, 7 days, 30 days, 3 months, 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="37a38b2d-8a13-401d-bfe3-40fa916d42c2">
	  <variable>WP4: Patient endocrine insufficiency score</variable>
	  <method>PEI-Q PROM</method>
	  <timepoints>discharge, 7 days, 30 days, 3 months, 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="91af81d0-1800-4a94-8957-ad2a1b18b4c4">
	  <variable>WP4: Healthcare utilisation following discharge</variable>
	  <method>Healthcare Utilisation PROM</method>
	  <timepoints>30 days, 3 months, 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="f3b26c3b-bf63-4e83-a5b8-2e1121adc9ed">
	  <variable>WP5: Identification of opportunities to implement the findings from WP1-4</variable>
	  <method>data from WP1-4 will be triangulated to identify commonalities and differences.  These analyses will form the basis of discussions in a one-day stakeholder workshop. Rolfe’s Co-reflective model ‘What?, So What?, Now What?’ will be used as a framework to identify opportunities to amend post-discharge pathways for patients following hospitalisation with acute pancreatitis</method>
	  <timepoints>the end of analysis of preceding WP1-4</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="523914b5-d289-42bd-a3e3-6cfc66aaa7f4" approvalStatus="approved" statusDate="2026-05-13T00:00:00.000Z">
	  <committeeName>South Central - Oxford B Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/SC/0148</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN30583116</doi>
      <eudraCTNumber/>
      <irasNumber>349680</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 64883, NIHR: 165210</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="fada9237-880f-40bc-b569-c081e9d1150f" numberType="iras" canonicalSecondaryNumber="IRAS349680">349680</secondaryNumber>
	<secondaryNumber id="7ef4157c-0d60-44d9-804a-5948dd4f6dec" numberType="cpms" canonicalSecondaryNumber="CPMS64883">64883</secondaryNumber>
	<secondaryNumber id="76abc018-accc-4fbf-a98b-04b0d76817f1" numberType="nihr" canonicalSecondaryNumber="NIHR165210">165210</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2027-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Scotland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="59a26d97-7e2c-4fcd-a834-c528816493c3">
	  <name>University Hospitals Birmingham NHS Foundation Trust</name>
	  <address>Queen Elizabeth Hospital
Mindelsohn Way
Edgbaston</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B15 2GW</zip>
	  <rtsId>RRK@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="aa1148cb-fecd-4bcc-9b48-2827b359afaf">
	  <name>Somerset NHS Foundation Trust</name>
	  <address>Trust Management
Lydeard House
Musgrove Park Hospital</address>
	  <city>Taunton</city>
	  <state/>
	  <country>England</country>
	  <zip>TA1 5DA</zip>
	  <rtsId>RH5@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="e5215641-a57f-4a0c-b180-961523284999">
	  <name>Leeds Teaching Hospitals NHS Trust</name>
	  <address>St. James's University Hospital
Beckett Street</address>
	  <city>Leeds</city>
	  <state/>
	  <country>England</country>
	  <zip>LS9 7TF</zip>
	  <rtsId>RR8@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="7f360bf6-23a2-4bc1-a793-cc28383a8bbf">
	  <name>Manchester University NHS Foundation Trust</name>
	  <address>Cobbett House
Oxford Road</address>
	  <city>Manchester</city>
	  <state/>
	  <country>England</country>
	  <zip>M13 9WL</zip>
	  <rtsId>R0A@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="56500cb9-9ebe-40ad-ba0c-f15265e9bfbc">
	  <name>York and Scarborough Teaching Hospitals NHS Foundation Trust</name>
	  <address>York Hospital
Wigginton Road</address>
	  <city>York</city>
	  <state/>
	  <country>England</country>
	  <zip>YO31 8HE</zip>
	  <rtsId>RCB@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="d3291b15-975c-44a0-87f2-2bdde0477925">
	  <name>Liverpool University Hospitals NHS Foundation Trust</name>
	  <address>Royal Liverpool University Hospital
Prescot Street</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L7 8XP</zip>
	  <rtsId>REM@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1cd6c86e-1b57-4a6c-9a5e-9858fa748114">
	  <name>Oxford University Hospitals NHS Foundation Trust</name>
	  <address>John Radcliffe Hospital
Headley Way
Headington</address>
	  <city>Oxford</city>
	  <state/>
	  <country>England</country>
	  <zip>OX3 9DU</zip>
	  <rtsId>RTH@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="20517c73-26f2-4690-807a-50dcbba14c5f">
	  <name>NHS Lothian</name>
	  <address>Waverley Gate
2-4 Waterloo Place</address>
	  <city>Edinburgh</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>EH1 3EG</zip>
	  <rtsId>SS999@2.16.840.1.113883.2.1.3.8.2.16.1</rtsId>
	</trialCentre>
	<trialCentre id="13ea8b37-9a4c-4ea0-8414-1bdb20719837">
	  <name>South Warwickshire University NHS Foundation Trust</name>
	  <address>Warwick Hospital
Lakin Road</address>
	  <city>Warwick</city>
	  <state/>
	  <country>England</country>
	  <zip>CV34 5BW</zip>
	  <rtsId>RJC@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="d57f2db2-4420-4230-bb22-54b6ed93c21e">
	  <name>University Hospitals Bristol and Weston NHS Foundation Trust</name>
	  <address>Trust Headquarters
Marlborough Street</address>
	  <city>Bristol</city>
	  <state/>
	  <country>England</country>
	  <zip>BS1 3NU</zip>
	  <rtsId>RA7@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="d070fa0d-82fd-4e5c-b871-b9bee8657645">
	  <name>Nottingham University Hospitals NHS Trust</name>
	  <address>Trust Headquarters
Queens Medical Centre
Derby Road</address>
	  <city>Nottingham</city>
	  <state/>
	  <country>England</country>
	  <zip>NG7 2UH</zip>
	  <rtsId>RX1@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="b303fec1-4ba2-4209-9b0a-dc2301512e15">
	  <name>Maidstone and Tunbridge Wells NHS Trust</name>
	  <address>The Maidstone Hospital
Hermitage Lane</address>
	  <city>Maidstone</city>
	  <state/>
	  <country>England</country>
	  <zip>ME16 9QQ</zip>
	  <rtsId>RWF@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="b896c2cc-acf0-4836-aa36-922afa015ea8">
	  <name>Gloucestershire Hospitals NHS Foundation Trust</name>
	  <address>Cheltenham General Hospital
Sandford Road</address>
	  <city>Cheltenham</city>
	  <state/>
	  <country>England</country>
	  <zip>GL53 7AN</zip>
	  <rtsId>RTE@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="64adbfec-2ee2-4efc-b2c7-03c85c6bb825">
	  <name>Torbay and South Devon NHS Foundation Trust</name>
	  <address>Torbay Hospital
Newton Road</address>
	  <city>Torquay</city>
	  <state/>
	  <country>England</country>
	  <zip>TQ2 7AA</zip>
	  <rtsId>RA9@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="a0d1b71b-104e-45cc-ad1a-e417103af543">
	  <name>Greater Glasgow and Clyde</name>
	  <address>Gartnavel Royal Hospital
1055 Great Western Road</address>
	  <city>Glasgow</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>G12 0XH</zip>
	  <rtsId>SG9@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="fbc30b0b-7cca-468e-a80a-eaf112152fbe">
	  <name>North Bristol NHS Trust</name>
	  <address>Southmead Hospital
Southmead Road
Westbury-on-trym</address>
	  <city>Bristol</city>
	  <state/>
	  <country>England</country>
	  <zip>BS10 5NB</zip>
	  <rtsId>RVJ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="02162c66-dfee-4409-ab9c-d549f482773e">
	  <name>University Hospitals of North Midlands NHS Trust</name>
	  <address>Newcastle Road</address>
	  <city>Stoke-on-trent</city>
	  <state/>
	  <country>England</country>
	  <zip>ST4 6QG</zip>
	  <rtsId>RJE@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="5ade0e76-330b-4474-9788-4b9e82aff36a">
	  <name>University Hospitals of Derby and Burton NHS Foundation Trust</name>
	  <address>Royal Derby Hospital
Uttoxeter Road</address>
	  <city>Derby</city>
	  <state/>
	  <country>England</country>
	  <zip>DE22 3NE</zip>
	  <rtsId>RTG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="797aa664-630c-4094-98ef-03ed884d8c8a">
	  <name>Forth Valley</name>
	  <address>Carseview House
Castle Business Park</address>
	  <city>Stirling</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>FK9 4TS</zip>
	  <rtsId>SV9@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="dff121eb-4d4a-49c4-bca4-91d0851d5486">
	  <name>The Shrewsbury and Telford Hospital NHS Trust</name>
	  <address>Mytton Oak Road</address>
	  <city>Shrewsbury</city>
	  <state/>
	  <country>England</country>
	  <zip>SY3 8XQ</zip>
	  <rtsId>RXW@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1524a894-4012-4643-aaad-0644a917a8a2">
	  <name>NHS Grampian</name>
	  <address>Summerfield House
2 Eday Road</address>
	  <city>Aberdeen</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>AB15 6RE</zip>
	  <rtsId>SN999@2.16.840.1.113883.2.1.3.8.2.16.1</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>WP1: Any lived experience of adult acute pancreatitis care in NHS as patient or carer, clinician providing NHS care to patients with acute pancreatitis in secondary or primary care.
WP2: Adults (or their carers) with experience of acute pancreatitis care in the NHS within the preceeding six months. Ideally have a conversational standard of English, but translation can be arranged.
WP3: Clinicians (surgeons, gastroenterologists, specialist nurses, allied health professionals, GPs) providing NHS care to patients with acute pancreatitis.
WP4: People currently admitted to hospital for acute pancreatitis who are due to be discharged. Must be able to consent to participate. 
WP5: Any lived experience of adult acute pancreatitis care in NHS as patient or carer, clinician providing NHS care to patients with acute pancreatitis in secondary or primary care.

Minimum age of participants in any work stream is 16 years old, and participants may be up to 100 years old.</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="16.0">16 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>1017</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>WP1: Must be able to complete survey in English
WP2: Must have experienced care as an adult
WP3: Non UK clinical practice
WP4: Unwilling to consent; no capacity to consent</exclusion>
      <recruitmentStart>2026-06-17T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute pancreatitis</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>There are 5 Work Packages (WP). These are complementary and intended to inform aspects of the final WP5 (see study summary graphic).

WP1: Survey
In order to ensure that themes addressed in the interviews cover all relevant aspects of post discharge care, we will undertake a short initial survey. This will recruit 20-40 from each group of patients/carers, secondary care clinicians (surgeons/gastroenterologists), nursing and allied health professionals, and general practitioners. The survey captures key demographic data, and asks participants to consider what opportunities exist to improve care after discharge, up to 6 months after acute pancreatitis.

WP2: Patient interviews
A topic guide has been prepared and will be refined with information from WP1. We will invite people with lived experience of acute pancreatitis to take part in a virtual interview of up to an hour.

People can register an interest in participation following links from posts on social media and through interest groups, charities, and the NIHR Be Part of Research registry. They will be asked to complete a short expression of interest form. The research team will review expressions of interest and aim to recruit people with a range of experiences by looking at age, gender, ethnicity, geographical region, and whether pancreatitis was related to gallstones.

When an appropriate participant is found, they will be contacted and the study further discussed with them. Should they wish to proceed, a digital consent form will be completed and a meeting arranged. The meeting will be conducted by a non clinical, experience qualitative researcher, and will be conducted by virtual meeting.

The interview will explore experience of post-discharge care after pancreatitis, and what the participant feels might improve this. Should the participant become distressed, the interview will be paused, and terminated if necessary. Signposting to resources such as charities will be undertaken.

Participation is complete at the end of the interview. The recording will be transcribed, and then dual coded by two researchers. A theoretical framework of post discharge needs will be developed using a thematic analysis approach. This will provide the patient perspective on post-discharge care.

WP3: Clinician interviews
A topic guide has been prepared and will be refined with information from WP1. We will invite clinicians who care for people with acute pancreatitis to take part.

People can register an interest in participation following links from posts on social media and emails through specialist clinical associations. They will be asked to complete a short expression of interest form. The research team will review expressions of interest and aim to recruit people with a range of experiences by looking at clinical role, and geographical region.

When an appropriate participant is found, they will be contacted and the study further discussed with them. Should they wish to proceed, a digital consent form will be completed and a meeting arranged. The meeting will be conducted by a non clinical, experience qualitative researcher, and will be conducted by virtual meeting.

The interview will explore experience of post-discharge care after pancreatitis, and what opportunities there are to improve this. This will explore ideas around clinical reasoning and assessment of disease and patient recovery.

Participation is complete at the end of the interview. The recording will be transcribed, and then dual coded by two researchers. A theoretical framework of post pancreatitis health risks and pathway opportunities will be developed. This will provide insight into clinical reasoning and priorities.

WP4: Cohort study
This will recruit people who are due to be discharged from hospital following an episode of acute pancreatitis drawing from several hospitals around the UK. Participants can be approached during their recovery and recruited up to the day of hospital discharge. This is supported by posters in the clinical area, a participant information sheet, and a short video.

If a participant consents, they will complete a set of questionnaires on the day of discharge. These relate to quality of life, mental health, and impact of disease on digestion. These are repeated at day 7, 28, 3 months, and 6 months. There is an additional questionnaire about alcohol use at baseline. We will ask about health service use at 28 days, 3 months, and 6 months post discharge.

Participants will receive reminders to complete by email, sms, or post. All post discharge contact is with the central research team. The questionnaires may take up to 30 minutes to complete.

If a participant reponds to mental health questionnaires indicating high risk of self harm, they will be contacted and advised to seek help via 111 or their GP.

This WP will provide data on health utilisation in the 6 months following discharge. It will provide novel data on the development of anxiety or depression, general quality of life, and patient reported symptoms of pancreatic exocrine insufficiency. We will use these data to construct models to allow us to stratify people who are most likely to use health care services following acute pancreatitis.

WP5: Implementation workshop
People who have shown interest in participation in previous WP will be invited to express interest in participating in a workshop to discuss the findings of the study. We will use purposive sampling to identify those to invite to the workshop. A PIS will be provided to those selected to participate, and consent secured.

This will continue until we have a minimum of 20 participants, 10 of whom are patients or carers, and the remainder a mix of health care professionals with roles in care of acute pancreatitis.

We will present the findings of the study to the whole group. We will then break off into smaller groups to discuss key themes. It is not yet clear what these are, but they may include dietary intervention, mental health support, stratified follow-up, pain management.

Smaller groups of 4-5 participants includind patients and clinicians will discuss a single theme. A facilitator will lead this, using a 'so what, now what' framework. This will encourage reflection, contextualising findings, and encouraging participants to share ideas on how to address these challenges.

We will take fields notes on the discussions and compile a list of 'recommendations to change practice' and 'recommendations for further research'. These ideas and reflections will be presented back to the wider group for comment.

We will share this list with policymakers, clinicians, patients, and researchers to influence future care.

Data will be held on secure servers. Expression of interest and cohort data including PROMS will be captured on REDCap hosted at the University of Birmingham. This is encrypted and password protected, using two factor authentication.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Data sharing statement to be made available at a later date</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="80ad58a7-8e9e-4a76-acfc-b2718e7a0743" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="b48a81a5-d3ce-4331-aaaa-6646e60da2c1" originalFilename="49694 PANORAMA WP2 - PIS (Carer) v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP2 - PIS (Carer) v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="248523" md5sum="0c2c4fce06c569ab0039972ad46c69fe"/>
	<description>WP2 (Carer)</description>
	<productionNotes/>
      </output>
      <output id="38ac5608-f8d3-4fab-9b4e-72c3d7e68440" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="a63d6196-1b78-491d-b4ef-7ad6d6509732" originalFilename="49694 PANORAMA WP2 - PIS (Patient) v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP2 - PIS (Patient) v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="247988" md5sum="86bc26aef761125d83fa7228ae598af0"/>
	<description>WP2 (Patient)</description>
	<productionNotes/>
      </output>
      <output id="76640f92-bca4-4e59-96bd-49eab92a985f" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="02eea570-22d3-4672-860a-8cb32432bd6b" originalFilename="49694 PANORAMA WP3 – Healthcare PIS v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP3 – Healthcare PIS v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="253412" md5sum="3ebf145b4440746a8ae06733c7764f3b"/>
	<description>WP3 (Healthcare)</description>
	<productionNotes/>
      </output>
      <output id="23b88566-8d40-4a14-ab0a-c8d6b438f0f5" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="cfc4980b-08c2-441e-aac5-bb5219f4839a" originalFilename="49694 PANORAMA WP4 - Participant Information Sheet v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP4 - Participant Information Sheet v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="250114" md5sum="ef709faad49a914d4bcf913e4b0b8b69"/>
	<description>WP4</description>
	<productionNotes/>
      </output>
      <output id="104c905e-6b19-4397-9d26-daa10ee825d9" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="d3ba6b4f-65ec-47eb-9025-005344c01869" originalFilename="49694 PANORAMA WP5 - Participant Information Sheet (Carer) v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP5 - Participant Information Sheet (Carer) v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="257031" md5sum="edda5912aa2bbb878b1cce268a8123b2"/>
	<description>WP5 (Carer)</description>
	<productionNotes/>
      </output>
      <output id="bc9ee307-6025-478c-9dd6-b05250eaccda" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="6a625896-ebb4-4e20-b995-e0bc91f924f8" originalFilename="49694 PANORAMA WP5 – Healthcare PIS v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP5 – Healthcare PIS v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="260109" md5sum="cfec9b3b67e8c1ec5e6999c60d96c23d"/>
	<description>WP5 (Healthcare)</description>
	<productionNotes/>
      </output>
      <output id="8d09ee35-cafd-4b03-a1c2-8f4f1895df47" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="b01b09f5-7cea-4a8f-bddb-15f3375ce1a8" originalFilename="49694 PANORAMA WP5 - Participant Information Sheet (Patient) v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP5 - Participant Information Sheet (Patient) v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="255957" md5sum="e5a8194c9a60351c48a8141029509917"/>
	<description>WP5 (Patient)</description>
	<productionNotes/>
      </output>
      <output id="74e800d3-ebf8-4e20-9957-e0f0f42494bb" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="140b17b8-7b62-4c82-b570-191a56b5aaa3" originalFilename="49694 PANORAMA PROTOCOL v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA PROTOCOL v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="1274826" md5sum="7d45197443eb0e6122b78f0d75c18bdd"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>a8302537-1fc8-48d8-bf9b-8017a0a1efa7</funderId>
      <contactId>45a86941-ef30-4088-9da9-fc9a6a7ec9e6</contactId>
      <contactId>4139f118-08af-43cf-b57e-17f39dd608da</contactId>
      <sponsorId>a99f577c-dde0-44d1-bfda-2b0d5029b807</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/b48a81a5-d3ce-4331-aaaa-6646e60da2c1/49694">
	<description>WP2 (Carer)</description>
	<name>49694 PANORAMA WP2 - PIS (Carer) v1.1 (11-May-2026).pdf</name>
	<id>b48a81a5-d3ce-4331-aaaa-6646e60da2c1</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>248523</length>
	<md5sum>0c2c4fce06c569ab0039972ad46c69fe</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/a63d6196-1b78-491d-b4ef-7ad6d6509732/49694">
	<description>WP2 (Patient)</description>
	<name>49694 PANORAMA WP2 - PIS (Patient) v1.1 (11-May-2026).pdf</name>
	<id>a63d6196-1b78-491d-b4ef-7ad6d6509732</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>247988</length>
	<md5sum>86bc26aef761125d83fa7228ae598af0</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/02eea570-22d3-4672-860a-8cb32432bd6b/49694">
	<description>WP3 (Healthcare)</description>
	<name>49694 PANORAMA WP3 – Healthcare PIS v1.1 (11-May-2026).pdf</name>
	<id>02eea570-22d3-4672-860a-8cb32432bd6b</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>253412</length>
	<md5sum>3ebf145b4440746a8ae06733c7764f3b</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/cfc4980b-08c2-441e-aac5-bb5219f4839a/49694">
	<description>WP4</description>
	<name>49694 PANORAMA WP4 - Participant Information Sheet v1.1 (11-May-2026).pdf</name>
	<id>cfc4980b-08c2-441e-aac5-bb5219f4839a</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>250114</length>
	<md5sum>ef709faad49a914d4bcf913e4b0b8b69</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/6a625896-ebb4-4e20-b995-e0bc91f924f8/49694">
	<description>WP5 (Healthcare)</description>
	<name>49694 PANORAMA WP5 – Healthcare PIS v1.1 (11-May-2026).pdf</name>
	<id>6a625896-ebb4-4e20-b995-e0bc91f924f8</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>260109</length>
	<md5sum>cfec9b3b67e8c1ec5e6999c60d96c23d</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/d3ba6b4f-65ec-47eb-9025-005344c01869/49694">
	<description>WP5 (Carer)</description>
	<name>49694 PANORAMA WP5 - Participant Information Sheet (Carer) v1.1 (11-May-2026).pdf</name>
	<id>d3ba6b4f-65ec-47eb-9025-005344c01869</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>257031</length>
	<md5sum>edda5912aa2bbb878b1cce268a8123b2</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/b01b09f5-7cea-4a8f-bddb-15f3375ce1a8/49694">
	<description>WP5 (Patient)</description>
	<name>49694 PANORAMA WP5 - Participant Information Sheet (Patient) v1.1 (11-May-2026).pdf</name>
	<id>b01b09f5-7cea-4a8f-bddb-15f3375ce1a8</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>255957</length>
	<md5sum>e5a8194c9a60351c48a8141029509917</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/140b17b8-7b62-4c82-b570-191a56b5aaa3/49694">
	<description>Protocol file</description>
	<name>49694 PANORAMA PROTOCOL v1.1 (11-May-2026).pdf</name>
	<id>140b17b8-7b62-4c82-b570-191a56b5aaa3</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>1274826</length>
	<md5sum>7d45197443eb0e6122b78f0d75c18bdd</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="45a86941-ef30-4088-9da9-fc9a6a7ec9e6">
    <title>Dr</title>
    <forename>Michala</forename>
    <surname>Pettitt</surname>
    <orcid>https://orcid.org/0000-0002-4736-259X</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Public Health Building
University of Birmingham</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 121 415 9106</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">panorama-study@contacts.bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="4139f118-08af-43cf-b57e-17f39dd608da">
    <title>Mr</title>
    <forename>Matt</forename>
    <surname>Lee</surname>
    <orcid>https://orcid.org/0000-0001-9971-1635</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Public Health Building
University of Birmingham</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.j.lee.1@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="a99f577c-dde0-44d1-bfda-2b0d5029b807">
    <organisation>University of Birmingham</organisation>
    <sponsorType>University/education</sponsorType>
    <rorId>https://ror.org/03angcq70</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="a8302537-1fc8-48d8-bf9b-8017a0a1efa7">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-08-03T12:19:38.66574629Z" version="17" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN59787438" publicIdentifierDateAssigned="2026-07-27T13:17:47.907031Z">
    <isrctn dateAssigned="2026-07-27T13:17:47.907031Z">59787438</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>A feasibility randomised controlled trial comparing VR-assisted nature therapy with an established online stress management intervention for individuals experiencing stress and anxiety</title>
      <scientificTitle>VR-assisted nature therapy versus online stress management: a randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>To evaluate the feasibility, acceptability, and preliminary effectiveness of Thrive Inside, a 12-week VR-assisted nature-based digital therapeutic intervention, compared with an established online stress management programme for adults experiencing stress and anxiety. The study also aimed to inform the design and implementation of a future definitive randomised controlled trial.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Stress and anxiety affect millions of people in the UK and are among the most common reasons for seeking mental health support. Long waiting times and increasing demand mean that many people do not receive help as quickly as they need it. There is therefore growing interest in developing accessible interventions that can support people experiencing stress and anxiety before symptoms become more severe.
Research has shown that spending time in nature may improve mental wellbeing. Virtual reality offers a way of delivering immersive nature-based experiences in a controlled and accessible way, enabling people to engage with therapeutic environments regardless of weather, location or mobility. Thrive Inside is a 12-week digital programme developed by EarthscapeVR that combines nature-based experiences, psychological education, breathing exercises, mindfulness and guided activities. Some participants also attend facilitated VR sessions using immersive nature environments.
The aim of this study is to evaluate whether Thrive Inside is practical and acceptable to deliver, and to compare it with an established online stress management programme based on cognitive behavioural principles. The study will also help determine whether a larger clinical trial should be undertaken in the future.

Who can participate?
Adults aged 18 to 66 years living in the United Kingdom who were experiencing mild to moderate symptoms of stress or anxiety

What does the study involve?
People interested in participating contacted the research team after seeing information about the study through TalkHealth and other recruitment materials. Those who met the eligibility criteria received detailed information about the study and provided informed consent before taking part.
Participants were randomly allocated to one of two groups.
The intervention group completed Thrive Inside, a 12-week online programme consisting of weekly learning modules, breathing exercises, mindfulness practices, nature-based activities and guided reflective exercises. Participants were also invited to attend three facilitated virtual reality sessions using immersive natural environments. Where attendance was not possible, equivalent two-dimensional (2D) video content was provided online.
The comparison group completed an established online stress management programme based on cognitive behavioural principles over the same 12-week period. They also received access to an NHS mindfulness body scan exercise.
Participants in both groups completed questionnaires before the programme began, during the intervention and after completing the programme. These questionnaires assessed stress, anxiety, mental wellbeing, life satisfaction and connectedness to nature. Participants also provided feedback about their experience of taking part.

What are the possible benefits and risks of participating?
Participants may learn techniques that help them manage stress, improve emotional wellbeing and develop healthy coping strategies. However, individual benefits cannot be guaranteed.
The study was considered low risk. Some participants may have experienced temporary emotional discomfort when completing questionnaires or reflecting on their wellbeing. Participants using VR could also experience mild side effects such as dizziness, eye strain or motion sickness. Participants were free to stop using the VR equipment or withdraw from the study at any time without giving a reason. Information about additional support services was available during study and afterwards.

Where is the study run from?
The study was sponsored and coordinated by EarthscapeVR Ltd in the United Kingdom. Recruitment was carried out primarily through TalkHealth, with participants completing most aspects of the study remotely from home. The study was conducted in collaboration with researchers from Birkbeck, University of London, the University of Liverpool and the University of Vienna (Austria).

When is the study starting and how long is it expected to run for?
November 2024 to August 2025

Who is funding the study?
The study was funded by Innovate UK, part of UK Research and Innovation (UKRI), through the Creative Catalyst programme (Grant No. 10117269). EarthscapeVR Ltd also provided the intervention platform, virtual reality content and study resources.

Who is the main contact?
Dr Annahita Nezami, annahita@earthscapevr.com</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="ff2b8eb4-3a8a-4ee0-a58a-a251ea0fe487">
	  <variable>Perceived stress</variable>
	  <method>the Perceived Stress Scale (PSS-10)</method>
	  <timepoints>baseline Week 0, mid-intervention (around weeks 3 - 6), and post-intervention (around week 14)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="22df8fa1-4769-4dcf-a0a3-8d92e3f8fce8">
	  <variable>Anxiety symptoms</variable>
	  <method>Generalized Anxiety Disorder-7 (GAD-7)</method>
	  <timepoints>baseline Week 0, mid-intervention (around weeks 3 - 6), and post-intervention (around week 14)</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="7fed38aa-38c1-4db1-b7c8-09a15e1ed117">
	  <variable>Mental well-being</variable>
	  <method>the Warwick–Edinburgh Mental Well-being Scale (WEMWBS)</method>
	  <timepoints>baseline Week 0, mid-intervention (around weeks 3 - 6), and post-intervention (around week 14)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="0731e324-3478-43dc-b308-cb23130a71c9">
	  <variable>Life satisfaction</variable>
	  <method>the Satisfaction With Life Scale (SWLS)</method>
	  <timepoints>baseline Week 0, mid-intervention (around weeks 3 - 6), and post-intervention (around week 14)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="b8380a6e-45ad-49f1-bb1a-a9f2f4461d0b">
	  <variable>Nature connectedness</variable>
	  <method>the Nature Relatedness Scale-6 (NR-6)</method>
	  <timepoints>baseline Week 0, mid-intervention (around weeks 3 - 6), and post-intervention (around week 14)</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="d9b2a6f6-9bd4-4289-9280-331d688aaddb" approvalStatus="approved" statusDate="2024-11-07T00:00:00.000Z">
	  <committeeName>London - West London &amp; GTAC Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>Health Research Authority, 2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>24/LO/0670</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN59787438</doi>
      <eudraCTNumber/>
      <irasNumber>345992</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber/>
      <secondaryNumbers>
	<secondaryNumber id="58b8ee56-84f0-4ebf-8234-64366b772fbb" numberType="iras" canonicalSecondaryNumber="IRAS345992">345992</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Prevention</purpose>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2025-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d4e26094-ae1a-41bc-8538-3e87d742978f">
	  <name>Talkhealth Partnership Limited</name>
	  <address>Landmark House, Station Road</address>
	  <city>Hook</city>
	  <state/>
	  <country>England</country>
	  <zip>RG27 9HA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Aged 18-66 years
2. Able to provide written informed consent 
3. Able to understand English sufficiently to provide written informed consent and understand the written content of the course (alternative language versions are planned for future versions of both the online course and VR content
4. Are aware of ongoing symptoms of mild-moderate anxiety or stress, e.g., over-worrying, nervousness, irritability, mood swings, difficulty concentrating, feeling overwhelmed, exhaustion, negative thoughts, avoidance or withdrawal from usual activities, appetite changes, sleep disturbances, and/or changes in routine
5. Have access to a laptop, mobile phone, or tablet with an internet connection to participate in the online course. The course is designed to be user-friendly and accessible across multiple devices, promoting greater inclusivity</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="66.0">66 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment>74</totalFinalEnrolment>
      <exclusion>1. No history of serious self-reported psychiatric or medical conditions
2. No current self-reported serious psychiatric symptoms, such as psychosis or eating disorders
3. No significant issues with vision and/or hearing loss
4. A diagnosis of, or chronic symptoms related to, anxiety disorders such as social anxiety, agoraphobia, health anxiety, panic disorder, or obsessive-compulsive disorder</exclusion>
      <recruitmentStart>2024-11-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2025-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mild-to-moderate levels of stress or anxiety</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants were allocated to either the Thrive Inside intervention group or the active control group after informed consent and enrolment. Microsoft Excel was used to generate a random allocation sequence using the binary values 0 and 1, with 0 representing the control group and 1 representing the Thrive Inside group. Each participant on the enrolment list was assigned to the corresponding value in the randomised sequence. The resulting allocation determined the participant’s study group. 

The intervention group received Thrive Inside, a 12-week multimodal digital therapeutic programme combining immersive virtual nature experiences, psychoeducation, mindfulness-based exercises, therapeutic activities, and optional group-based VR sessions designed to promote stress reduction, emotional regulation, and nature connectedness. Participants who were unable to attend immersive sessions accessed equivalent two-dimensional (2D) content remotely. The comparator group received an established online stress management programme based on cognitive behavioural principles, delivered over the same 12-week period.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>An anonymised participant-level dataset, study protocol, statistical analysis code and supporting documentation will be deposited in the Open Science Framework (OSF) repository following publication. The data will be made available indefinitely for research purposes. All shared data will be anonymised in accordance with UK GDPR, participant consent and ethical approval.

OSF Link 
https://osf.io/nd8zg/overview?view_only=a494ae5ae57441159d1103c9881467be</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Stored in publicly available repository</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="84c403d4-ab0e-430b-9f7a-22e8a3e41979" outputType="dataset" artefactType="ExternalLink" dateCreated="2026-07-27T00:00:00.000Z" dateUploaded="2026-08-03T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<externalLink url="https://osf.io/nd8zg/overview?view_only=a494ae5ae57441159d1103c9881467be"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="875e05b1-98ec-4d22-80b1-a8f47ef833f3" outputType="protocolother" artefactType="ExternalLink" dateCreated="2026-07-27T00:00:00.000Z" dateUploaded="2026-08-03T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<externalLink url="https://osf.io/nd8zg/overview?view_only=a494ae5ae57441159d1103c9881467be"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>8e94cc6a-9d0f-447e-9819-58219cd13d2e</funderId>
      <contactId>a04348fc-aa18-4be8-868c-43e7f97b70ea</contactId>
      <sponsorId>729c244a-7cc7-4d38-ad47-ab5c31c5bf11</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="a04348fc-aa18-4be8-868c-43e7f97b70ea">
    <title>Ms</title>
    <forename>Annahita</forename>
    <surname>Nezami</surname>
    <orcid>https://orcid.org/0009-0003-9705-758X</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>71-75, Shelton Street, Covent Garden</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>WC2H 9JQ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">annahita@earthscapevr.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="729c244a-7cc7-4d38-ad47-ab5c31c5bf11">
    <organisation>EarthscapeVR LTD</organisation>
    <sponsorType/>
    <commercialStatus>Commercial</commercialStatus>
  </sponsor>
  <funder id="8e94cc6a-9d0f-447e-9819-58219cd13d2e">
    <name>Innovate UK</name>
    <fundRef>http://dx.doi.org/10.13039/501100006041</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-05-21T12:15:58.082038511Z" version="22" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN88133553" publicIdentifierDateAssigned="2026-05-21T12:15:58.310878Z">
    <isrctn dateAssigned="2026-05-21T12:15:58.310878Z">88133553</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A staged dose-finding and challenge/rechallenge study of Staphylococcus aureus nasal colonisation in healthy adults</title>
      <scientificTitle>ReSET – Rechallenge Staphylococcus aureus Experimental nasal colonisation sTudy</scientificTitle>
      <acronym>ReSET</acronym>
      <studyHypothesis>Primary objectives:
Stage I: To determine the safety of S. aureus primary challenge in humans
Stage I co-primary: To determine the challenge doses required to achieve a 50-70% nasal colonisation rate with up to two strains of S. aureus
Stage II: To determine the safety of S. aureus primary challenge and rechallenge in humans
Stage II co-primary: To quantify the rate of S. aureus acquisition following primary challenge, homologous rechallenge ± heterologous rechallenge

Secondary objectives:
1. To explore immunological and microbiological markers including those induced by S. aureus exposure and how those may predict protection against re-infection
2. To describe pre-decolonisation S. aureus carriage within the study population
3. To determine time-course and bacterial density of colonisation with challenge strains
4. To determine rates and extent of colonisation spread to extra-nasal sites with challenge strains</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Staphylococcus aureus is a common bacterium that many people carry in their noses without feeling unwell. In some people it can lead to infections, but we do not fully understand why it lives harmlessly in some individuals and not others. This study aims to learn more about how the bacterium settles in the nose and whether being exposed once can protect someone from becoming colonised again in the future. To do this, the study team will place a small, carefully measured amount of the bacterium into the noses of healthy adult volunteers and monitor them closely.

Who can participate?
Healthy adults aged 18 to 55 years who meet the detailed health and lifestyle criteria set by the study team.

What does the study involve?
Participants will first attend a screening visit, where their general health will be checked. If eligible, they will then complete a standard 5 day course of decolonisation treatment that includes a nasal antibiotic ointment and an antiseptic hair and body wash. About two weeks later, they will return to receive the challenge, which means a small amount of Staphylococcus aureus will be dripped into their nose.

Participants will record any symptoms each day for 28 days, with some days involving in-person visits for safety checks, blood tests and nose or body swabs. They will take some nose samples at home using equipment provided. After this follow-up period, they will repeat the decolonisation treatment. Some participants may be invited to take part in a second challenge later in the study, depending on whether they became colonised the first time.

What are the possible benefits and risks of participating?
Participants will be contributing to important research that may help scientists develop new ways to prevent or treat Staphylococcus aureus infections in the future. However, taking part carries some risks. Mild infections such as small skin spots or pimples can occur, though more serious infections are uncommon in healthy adults. There is a small chance volunteers could pass the bacteria to others, so they must avoid close contact with vulnerable people for a period of time. Blood tests may cause slight pain or bruising, and nasal swabs can be a little uncomfortable. The decolonisation products may cause mild irritation or, rarely, allergic reactions. Antibiotics will only be used if necessary.

Where is the study run from?  
The study is run in Oxford, United Kingdom, at the Centre for Clinical Vaccinology and Tropical Medicine at Churchill Hospital.

When is the study starting and how long is it expected to run for?  
April 2026 to December 2029.

Who is funding the study?  
Ellison Institute of Technology (UK)

Who is the main contact?  
Mr Conor Whelan at the Centre for Clinical Vaccinology and Tropical Medicine in Oxford.
conor.whelan@paediatrics.ox.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="169d3dcb-df63-4dff-ad24-816484963ee7">
	  <variable>Stage I: Occurrence of solicited and unsolicited adverse events, serious adverse events and adverse events of special interest</variable>
	  <method>clinical assessment and safety reporting</method>
	  <timepoints>D0–D6 (solicited), D0–D28 (unsolicited), study duration (SAEs &amp; AESIs)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="d7b7cdcf-b541-4050-b417-4dee9c4cfb0c">
	  <variable>Stage I: Presence of Staphylococcus aureus in nasal wash</variable>
	  <method>culture based microbiology</method>
	  <timepoints>D3–D10</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="e2fea707-b09d-4acc-b66d-7ff529e3b17d">
	  <variable>Stage II: Occurrence of solicited and unsolicited adverse events, serious adverse events and adverse events of special interest</variable>
	  <method>clinical assessment and safety reporting</method>
	  <timepoints>D0–D6 (solicited), D0R1–D6R1, D0–D28, D0R1–D28R1 (unsolicited), study duration (SAEs &amp; AESIs)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="1c993b7c-e6dd-49a5-bd15-eb186d3fdfe5">
	  <variable>Stage II: Presence of Staphylococcus aureus challenge strain in nasal wash</variable>
	  <method>culture based microbiology</method>
	  <timepoints>D3–D28, D3R1–D28R1</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="dec6c0fe-88e6-4b6b-9ce2-4d8450b01fd7" approvalStatus="submitted" statusDate="2026-03-19T00:00:00.000Z">
	  <committeeName>South Central - Berkshire REC</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/SC/0123</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88133553</doi>
      <eudraCTNumber/>
      <irasNumber>366748</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 71824</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="a3051b6b-b2f5-4a59-aaf7-542b808e773a" numberType="iras" canonicalSecondaryNumber="IRAS366748">366748</secondaryNumber>
	<secondaryNumber id="aa0f2dd3-a76e-4d14-9aa1-1394da69b56c" numberType="cpms" canonicalSecondaryNumber="CPMS71824">71824</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2029-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="23c27487-7c9f-486a-bd28-1b40db0f3dbc">
	  <name>Oxford Vaccine Group</name>
	  <address>Old Road
Headington</address>
	  <city>Oxford</city>
	  <state/>
	  <country>England</country>
	  <zip>OX3 7LE</zip>
	</trialCentre>
	<trialCentre id="097590f4-f209-47a9-847d-d5a2de42b166">
	  <name>Liverpool Vaccine Group</name>
	  <address>Liverpool School of Tropical Medicine, Accelerator Building, 1 Daulby Street</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L7 8XZ</zip>
	</trialCentre>
	<trialCentre id="11204932-9298-44b9-bccc-76018a73f9cc">
	  <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
	  <address>Northern General Hospital
Herries Road</address>
	  <city>Sheffield</city>
	  <state/>
	  <country>England</country>
	  <zip>S5 7AU</zip>
	  <rtsId>RHQ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="b8fe6ab1-b0dc-4b90-a069-0a5fe1dd23cb">
	  <name>Oxford University Hospitals NHS Foundation Trust</name>
	  <address>John Radcliffe Hospital
Headley Way
Headington</address>
	  <city>Oxford</city>
	  <state/>
	  <country>England</country>
	  <zip>OX3 9DU</zip>
	  <rtsId>RTH@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>true</healthyVolunteersAllowed>
      <inclusion>1. Adults between 18 to 55 years old (inclusive) at the time of enrolment (defined by the start of first decolonisation therapy)
2. Medically healthy, such that according to investigator judgement, hospitalisation within the study period is not anticipated, and the participant appears likely to be able to remain a study participant through to the end of protocol-specified follow-up. Planned elective procedures for pre-existing conditions may be allowable if S. aureus colonisation is not deemed to put the participant at increased risk of harm and if the elective procedure does not routinely involve, and is not likely to involve, decolonisation and/or antibiotic therapy
3. Fluent spoken English – to ensure a comprehensive understanding of the research project and their proposed involvement
4. Capacity to provide written informed consent in English for participation in the study 
5. Able to attend the scheduled visits and to comply with all study procedures, including internet access for the recording of electronic diaries after issue of decolonisation therapy and S. aureus challenge
6. Able to follow and adhere to hygiene advice as well as the decolonisation protocol which includes daily shower and hair wash
7. Willing and able to avoid planned, non-essential non-study antibiotics for the duration of the study
8. Willing and able to avoid intranasal and inhaled products (including nasal steroids) unless prescribed by the study team for the duration of the study 
9. Able to adhere to standard hygiene advice at home
10. Willing to allow confirmation of past medical history either through provision of, or access to, a medical record summary or other medical documentation or to allow investigators to obtain a copy of their medical history via their GP practice or via electronic patient records
11. Willing to allow their GP and/or consultant, if appropriate, to be notified of participation in the study
12. Willing to provide their national insurance number or passport number to be registered on The Trial Over-Volunteering Prevention System (TOPS)
13. For participants of childbearing potential only: Willing to use effective contraception for the duration of the study AND to have a pregnancy test on the day of screening, and challenge or as indicated by the study doctor</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="55.0">55 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>384</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1.  Research participants  
    1.1. Participation in another research study in which procedures could compromise the integrity of this study (for example immune modulating or stimulating treatments) or the safety of the participant (for example significant volumes of blood taken), or planning to do so within the study period
2.  Vaccination (self-reported with or without confirmation from GP questionnaire or medical records or summary if deemed necessary at clinician discretion)  
    2.1. Planned vaccination in the two months following final challenge  
    2.2. Live vaccination within the 4 weeks prior to first challenge
3.  Allergy  
    3.1. Have an allergy or intolerance to beta-lactam antibiotics  
    3.2. Have an allergy or intolerance to more than one of doxycycline, co-trimoxazole, clindamycin and linezolid  
    3.3. Have an allergy or intolerance to any of the agents used for decolonisation
4.  Specific health history (self-reported with or without confirmation from GP questionnaire or medical records or summary if deemed necessary at clinician discretion)  
    4.1. History of severe S. aureus infection, including PVL-associated disease  
    4.2. Atopic dermatitis  
    4.3. Psoriasis, eczema or other chronic skin condition requiring treatment in the last year  
    4.4. Compromised skin barrier function at the discretion of the investigator  
    4.5. Known structural heart issues at the discretion of the investigator, including but not limited to PFO, VSD and bicuspid AV  
    4.6. Implanted prosthetic material including but not limited to cochlear implants, orthopaedic implants, implantable cardiac devices, cardiac valves and neurological stimulators  
    4.7. Recurrent sinusitis  
    4.8. Previous sinus surgery  
    4.9. Planned surgical, dental, orthodontic, dental hygienist or pre-operative appointment over the study period
5.  General health history (self-reported and or confirmed from GP questionnaire or medical records or summary if deemed necessary). Moderate to severe ill health including but not limited to:  
    5.1. Asplenia or dysfunction of the spleen  
    5.2. Chronic respiratory disease (for example asthma on medication, COPD, emphysema, bronchiectasis)  
    5.3. Chronic heart disease (for example angina, ischaemic heart disease, chronic heart failure). Controlled stable hypertension with or without angina may be included  
    5.4. Chronic kidney disease (for example nephrotic syndrome, kidney transplant, on dialysis)  
    5.5. Chronic liver disease (for example cirrhosis, biliary atresia, hepatitis)  
    5.6. Chronic neurological conditions  
    5.7. Connective tissue disease  
    5.8. Dementia  
    5.9. Diabetes mellitus (including diet controlled)  
    5.10. Immunosuppression or history of receiving immunosuppressive therapy at the discretion of the investigator  
    5.11. Individuals with cochlear implants  
    5.12. Individuals with major cerebrospinal fluid leaks (for example following trauma, major skull surgery or requiring CSF shunt)  
    5.13. History of a bleeding disorder (for example factor deficiency, coagulopathy or platelet disorder) or prior history of significant bleeding or bruising following IM injections or venepuncture  
    5.14. Any uncontrolled medical, surgical or mental health conditions at the discretion of the study doctor  
    5.15. Significant mental health condition (for example previous admissions in a psychiatric unit, at the discretion of the clinician) that would impair the participant’s ability to participate in the study
6.  Taking medications  
    6.1. Any medication that may affect the immune system in the last 3 months (for example systemic steroids PO or IM or IV, Roaccutane, disease-modifying anti-rheumatoid drugs)  
    6.2. Current or intended long-term or intermittent use of antibiotics over the course of the study  
    6.3. Recent systemic antibiotic exposure in the last 1 month  
    6.4. Use of any medication affecting blood clotting (any oral or injectable anticoagulants) except for aspirin for secondary cardiovascular prevention  
    6.5. Use of any medication or other product (prescription or over-the-counter) for symptoms of rhinitis or nasal congestion within 4 weeks of enrolment
7.  Volunteers who are pregnant, lactating or intending on becoming pregnant during the study
8.  Volunteers who have close contact with individuals at higher risk of infection  
    8.1. Children under 5 years of age  
    8.2. Chronic ill health or immunosuppression (adults or children)  
    8.3. Older adults aged 65 years or above  
    8.4. Household close contact with compromised skin barrier function, psoriasis, eczema or other chronic skin condition requiring treatment in the last year
9.  Volunteers (including healthcare workers) who have close contact in high-risk occupational settings or with high-risk or vulnerable individuals during the study
10. Smoker  
    10.1. Current or ex-smoker (regular cigarettes, cigars, e-cigarette, vaping or smoking of recreational drugs) in the last 6 months  
    10.2. Previous significant smoking history (more than 20 cigarettes per day for 20 years or the equivalent, meaning 20 pack years or above)
11. Suspected or known current hazardous or harmful alcohol or drug use, as per investigators’ discretion
12. Intended overseas travel during the course of the study
13. Any other issue which, in the opinion of the study staff, may:  
    13.1. Put the participant or their contacts at risk because of participation in the study  
    13.2. Adversely affect the interpretation of the study results  
    13.3. Impair the participant’s ability to participate in the study
14. Study staff or a partner or dependent child of study staff
15. Household close contact previously or currently involved in this study, provided they have received challenge
16. Stage 2 exclusion only: enrolment in Stage 1</exclusion>
      <recruitmentStart>2026-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Staphylococcus aureus nasal colonisation</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This study is a two-stage, unblinded, strain-randomised Controlled Human Infection Model (CHIM). It is multicentre, starting in one location with sequential opening of UK locations as required. It is designed to develop and evaluate a safe method of establishing temporary nasal colonisation with Staphylococcus aureus in healthy adults aged 18 to 55 years.

In stage I the aim is to find the best challenge dose of up to two strains of S. aureus in order to achieve colonisation in 50 to 70 percent of volunteers. Up to four strains of S. aureus will be trialled and the continuous reassessment method (CRM) will be used to identify the challenge dose. Up to 48 participants per strain will be enrolled.

Participants will be screened up to 6 months in advance of enrolment. Screening will involve written consent, a urine test for pregnancy where appropriate, blood tests to check general markers of health, a physical examination and measurement of vital signs. A medical and medication history will be taken. Next of kin information will be requested and they will be provided with a household contact information sheet. Details will also be taken to allow registration on TOPS (trial over-volunteering prevention service) and to allow reimbursement for time and inconvenience.

Once enrolled, participants will undergo a 5 day course of standardised decolonisation therapy (nasal antibiotic ointment and antiseptic hair and body wash) starting about 2 weeks before challenge. Participants will have a decolonisation e-diary to record adherence. They will be reviewed about 4 days before challenge for nose samples, body swabs and blood tests.

At challenge they will receive a carefully measured dose of liquid containing the candidate strain by dripping it into the nose. The dose will be determined by the continuous reassessment method, which takes into account the proportion of participants colonised up to that point to ensure the best chance of achieving a colonisation rate in the target range.

Participants will be followed up with a daily symptom e-diary for safety reasons. This lasts 28 days with a more intensive phase lasting 7 days. There will be a series of more time-intensive in-person reviews on days 1, 3, 7, 10 and 16 after challenge. These reviews are for safety monitoring as well as blood, nose and body swab sampling to check for immune responses and presence of bacteria. On days without in-person review, participants will take nose samples at home and store them in the freezer using provided equipment. Additional home samples will be requested on day 22 and day 42.

There will be a further in-person visit on day 28 for blood, nose and body swab sampling. Participants will then be given a further 5 day course of decolonisation therapy. Two follow up visits by phone or email will occur on day 56 and day 182 for safety review.

Up to four strains will be trialled, but only up to two strains will progress to stage II once predefined criteria are met, including an estimated colonisation probability within the target range and no safety concerns. If no strain meets criteria, the study will stop. A formal DSMB safety review will be conducted before progression to stage II. Up to 48 participants will be challenged per strain, with a maximum of 192 for stage I.

The purpose of stage II is to assess whether colonisation after one challenge offers any protection against colonisation after a second challenge. A new set of participants will be recruited. Participants will be randomised 1:1 to receive either the first or second strain (at the doses selected in stage I) for their primary challenge. Only participants who become colonised at primary challenge will proceed to rechallenge.

Participants will undergo a very similar process to stage I, but the day 56 visit will be in-person and this is when they will receive their second decolonisation. Participants not successfully colonised after primary challenge will have their final contact with the study team at the day 182 phone or email visit.

Participants successfully colonised after primary challenge will undergo a second decolonisation starting at day 56. The schedule of visits will then repeat with a pre-challenge visit, rechallenge on day 70, and a more intensive follow up period lasting until 56 days after rechallenge, when they will receive their third decolonisation course. Their final contact will be a phone or email visit at day 182 after rechallenge.

Rechallenge will initially use the same strain as at primary challenge. The study team will review data as the study progresses, supported by formal interim analyses of rechallenge colonisation rates. Broadly, once 20 participants have demonstrated protection, the strain used for rechallenge will switch from the same strain used at primary challenge to the other strain in stage II, to assess whether protection applies across strains.

If only one strain progresses from stage I to stage II, there will be no randomisation and the same strain will be used for both primary challenge and rechallenge. Participants not colonised at primary challenge will not undergo rechallenge and will be followed up for approximately six months. Up to 192 participants will be enrolled in stage II.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>As part of this study, the University of Oxford will share relevant research data with the Ellison Institute of Technology, Oxford. The data they receive will not include participants names, contact details, NHS number or other direct identifiers. The data will be labelled only with a code.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Other</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>ddf94934-7b95-4b75-af83-188db229b789</funderId>
      <contactId>9726a45e-57e3-492e-90a5-c0322a3db06b</contactId>
      <contactId>3985d5ec-1cec-4422-a3de-e248965813db</contactId>
      <sponsorId>ef0990a1-5395-43b0-bec1-9d78db86f4f0</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="9726a45e-57e3-492e-90a5-c0322a3db06b">
    <title>Mr</title>
    <forename>Conor</forename>
    <surname>Whelan</surname>
    <orcid/>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Churchill Hospital, Annexe Reception, Centre for Clinical Vaccinology and Tropical Medicine</address>
      <city>Oxford</city>
      <state/>
      <country>United Kingdom</country>
      <zip>OX3 7LE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 1865611400</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">conor.whelan@paediatrics.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="3985d5ec-1cec-4422-a3de-e248965813db">
    <title>Prof</title>
    <forename>Andrew</forename>
    <surname>Pollard</surname>
    <orcid>https://orcid.org/0000-0001-7361-719X</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Churchill Hospital, Annexe Reception, Centre for Clinical Vaccinology and Tropical Medicine</address>
      <city>Oxford</city>
      <state/>
      <country>United Kingdom</country>
      <zip>OX3 7LE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 1865611400</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andrew.pollard@paediatrics.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="ef0990a1-5395-43b0-bec1-9d78db86f4f0">
    <organisation>University of Oxford</organisation>
    <sponsorType>University/education</sponsorType>
    <rorId>https://ror.org/052gg0110</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="ddf94934-7b95-4b75-af83-188db229b789">
    <name>Elliston Institute of Technology</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-04-22T08:11:18.214760658Z" version="13" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN12055450" publicIdentifierDateAssigned="2026-04-22T08:11:18.445479Z">
    <isrctn dateAssigned="2026-04-22T08:11:18.445479Z">12055450</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Respiratory-swallow training in head and neck cancer</title>
      <scientificTitle>Evaluating the feasibility of a respiratory-swallow training intervention to improve swallow function for people with head and neck cancer</scientificTitle>
      <acronym>ReST-HN</acronym>
      <studyHypothesis>This study aims to:
1.  Develop a training package for speech and language therapists
2.  Train speech and language therapists to use the programme with patients
3.  Carry out a study to examine how the training programme would work in practice, using a biofeedback approach
4.  Determine whether the project is feasible and likely to be effective within the NHS</studyHypothesis>
      <plainEnglishSummary>Background and study aims
The problem:
In the United Kingdom, 12,200 people are diagnosed with head and neck cancer every year. Difficulties swallowing food and drink following cancer of the head and neck are common. Swallowing difficulties often arise due to the position of the tumour itself (which may be found in the mouth, tongue, voicebox or throat) and after treatment (surgery, chemotherapy and/or radiotherapy). Swallowing difficulties may last a long time and can lead to problems such as fear of eating, losing weight, chest infections, and even death. Swallowing difficulties can also have a negative impact on an individual’s mental health. These difficulties can affect how people interact with others and whether they take part in enjoyable activities. Unfortunately, exercises designed to improve swallowing do not always work for a lot of patients with head and neck cancer. This means we need to look for new ways of improving swallowing.
The solution:
New training, which aims to change the breathing-swallowing pattern of patients with swallowing difficulties, has been developed in America. It seems to work well and improves swallowing for people with head and neck cancer. However, this training programme requires a lot of equipment and training to work. We plan to simplify this training and use equipment that is easy to use, both for therapists and patients. This will benefit patients because, if it works, it will be available to lots of people and can be used at home.
This study aims to:
•	develop a training package for speech and language therapists and patients.
•	train speech therapists to use the programme with patients.
•	to see how the training programme works in practice, using simple, easy to use equipment to help coordinate breathing and swallowing
•	find out about whether the project is doable, likely to work in the NHS and worth investing in.
•	ask patients and therapists about what they think of the training and whether it can be improved.

Who can participate?
You may be able to take part if you:
•	have been diagnosed with swallowing difficulties (dysphagia) by your speech and language therapist or have had a swallow test.
•	have completed treatment (surgery, radiotherapy, and/or chemotherapy) for head and neck cancer for the first time.
•	finished your cancer treatment at least 3 months ago, with treatment given to try to cure the cancer.
•	are 18 years of age or older.
•	are able to drink fluids  (of any thickness)
•	are able to hold drink in the mouth and then continue breathing through the nose

What does the study involve?
On your first appointment
We need to check that the study is suitable for you. The researcher will test your:
1.	breathing-swallowing pattern. You will be asked to wear special equipment. The equipment will include monitors under your chin and nose and around your chest and stomach .
2.	lung range. You will also be asked to blow into a device (called a spirometer) to test the amount of air going in and out of your lungs.
3.	swallowing ability. If you have not recently completed a formal examination of your swallow, such as a swallow x-ray (videofluoroscopy) or via a camera passed through the nose (flexible endoscopic evaluation of swallowing (FEES)), you will be asked to complete a FEES test. During the procedure a thin, flexible instrument is passed through your nose. The parts of your throat can then be seen as you swallow liquids and foods.

It will take approximately 15-35 minutes depending on whether you need a swallow test. If you need a swallow test this appointment will need to take place at an NHS clinic, otherwise we can see you at home, if you’d prefer. You may be unable to take part in the study if your breathing-swallowing pattern or swallowing ability is within the normal range or you have a severe lung condition.

There will be two groups:
1. One group will act as a control (with no training)
2. One group will receive training using equipment (biofeedback)
 
If you are able to take part in the study, a computer will randomly choose whether you will be in one of the swallow training groups or the control group (no swallow training). You have a 50% chance of being in one of the training groups and a 50% chance of being in the control group. We get a computer to do this job because we think this is fairest. There are no people making decisions about which person is in which group.

At your second appointment you will fill out some surveys about your swallowing difficulties. At the same appointment your breathing-swallow pattern will be measured. These tests will take about 30 minutes. You will also have an x-ray video of your swallowing (videofluoroscopy).  In the examination you will be asked to swallow a range of foods and drinks of different consistencies. Barium will be added to the food and drink so it shows up clearly on the x-ray. The x-ray will take about 15 minutes.

Swallow training
If you are selected to take part in the swallow training, a speech and language therapist will see you once a week (for up to an hour) for up to 6 weeks. The training will focus on changing the timing of your swallow whilst you drink. If you are selected to train using the equipment you will be asked to wear a respiratory belt around your chest.  If you are unable to manage certain drinks or foods the training will be tailored to your needs. These treatment appointments will be videoed so that the research team can monitor whether the training is following the guidelines. The training sessions will take place at an NHS clinic or at your home, depending on your therapist or your preference. After the training is completed, we will be unable to offer you further training in this technique.
 
Will I need to attend any other appointments?
You will be invited to attend another two appointments, one week after the training and three months later, even if you are in the control group (no training). Each appointment will last about 45 minutes. The tests completed at your second appointment will be repeated at each follow up appointment. These will include: 1) surveys, 2) measurement of your swallowing (x-ray), and, 3) assessments of your breathing-swallowing pattern. These appointments will take place at an NHS clinic.
 
You may be invited to an interview to talk about what your experience of taking part in the study was like. This might be during training or after training. Interviews will be audio-recorded and will last up to an hour. You can decide whether or not you would like to take part.

You will receive £20 and travel for every appointment you attend once you are taking part in the study.

What are the possible benefits and risks of participating?
The videofluoroscopy (video x-ray of the swallow) generates real-time moving pictures using radiation. We are all exposed to natural background radiation every day in our environments. The x-ray will give you additional radiation on top of your natural background radiation. Your radiation exposure for each videofluoroscopy is small, about the same as 2-7 weeks of natural background radiation, which you normally receive every day.
 
If you need a swallow test using an endoscope (FEES) it is possible that you may experience mild discomfort. You will have had one of these before with your ENT doctor. There is a small chance you might have a nose bleed (1%), however this is very rare.

Where is the study run from?
The study is run from the University of Liverpool, UK
You may be eligible to take part in the study if you live in Merseyside or Cheshire.

When is the study starting and how long is it expected to run for?
The study is starting in May 2026 and finishing in February 2028

Who is funding the study?
The National Institute for Health and Care Research (NIHR) funds this study (303061)

Who is the main contact?
 The chief Investigator is Dr Michelle Lawton, Michelle.Lawton@liverpool.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="51b22a69-6e22-4a0d-a43b-b529da176b1c">
	  <variable>Intervention uptake</variable>
	  <method>Screening and enrolment logs recording number of eligible patients and number consenting</method>
	  <timepoints>Throughout recruitment period</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="8bb749ab-16a4-493c-bbc8-1c3f8d2abc51">
	  <variable>Acceptability of the intervention</variable>
	  <method>Semi-structured qualitative interview</method>
	  <timepoints>during and following the intervention</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="1d86f5bd-b2f9-43a9-830b-bb9b886b4fd9">
	  <variable>Acceptability of randomisation</variable>
	  <method>Semi-structured qualitative interview</method>
	  <timepoints>during and following the intervention</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="1eaa1bf1-1848-43db-b035-4a2a1d58e9c6">
	  <variable>Completeness of outcome measures</variable>
	  <method>assessment completion records calculating percentage completed</method>
	  <timepoints>3 month follow up</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="5b603188-98bd-4a5f-bf56-16a48c9b6dd5">
	  <variable>Adherence to treatment manual</variable>
	  <method>Treatment fidelity checklist scored from video-recorded sessions</method>
	  <timepoints>During intervention period</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="1d17f7b3-40ce-4659-a08c-4fbf957e614f">
	  <variable>Determinants of implementation and mechanisms of change</variable>
	  <method>Semi-structured qualitative interview</method>
	  <timepoints>during and following the intervention</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="c61c261e-8b2b-42eb-a6e0-27327073a634">
	  <variable>Respiratory swallow coordination</variable>
	  <method>Respiratory inductance plethysmography, nasal airflow and submental surface electromyography analysed using LabChart software</method>
	  <timepoints>Baseline, post intervention, 3 month follow up</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="fb6b1d64-7c69-4980-877d-bd5c5263c655">
	  <variable>Lung volume during swallowing</variable>
	  <method>Respiratory inductance plethysmography calibrated to lung volume estimates</method>
	  <timepoints>Baseline, post intervention, 3 month follow up</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="4b6bd23d-0000-4908-9972-d4bae569d9c8">
	  <variable>Respiratory swallow pattern</variable>
	  <method>respiratory inductance plethysmography and nasal airflow recordings</method>
	  <timepoints>Baseline, post intervention, 3 month follow up</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9481323e-d253-4489-a598-117889ce41e2">
	  <variable>Respiratory pause duration during swallowing</variable>
	  <method>nasal airflow recordings</method>
	  <timepoints>Baseline, post intervention, 3 month follow up</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="db6a5fe6-6da5-4619-ada8-3703274809de">
	  <variable>Swallow safety</variable>
	  <method>Penetration Aspiration Scale scored from videofluoroscopic swallow study</method>
	  <timepoints>Baseline, post intervention, 3 month follow up</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="26a614d5-4032-47f2-947c-e827d2ad6dbc">
	  <variable>Swallow physiology and impairment</variable>
	  <method>Modified Barium Swallow Impairment Profile scored from videofluoroscopic swallow study</method>
	  <timepoints>Baseline, post intervention, 3 month follow up</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="23b48991-47ec-45d5-b8c0-52fe841787c9">
	  <variable>Swallow related quality of life</variable>
	  <method>MD Anderson Dysphagia Inventory questionnaire</method>
	  <timepoints>Baseline, post intervention, 3 month follow up</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="eb64238a-9eb9-4691-8c18-0ccba0e332bb">
	  <variable>Functional swallow performance</variable>
	  <method>Performance Status Scale for Head and Neck Cancer</method>
	  <timepoints>Baseline, post intervention, 3 month follow up</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="8410b0f8-bd79-4b18-b98d-dad426eb3199">
	  <variable>Pulmonary function</variable>
	  <method>Spirometry measuring forced expiratory volume in 1 second and forced vital capacity ratio using a digital spirometer</method>
	  <timepoints>Baseline only</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="bf9f684d-424c-4f62-bb3b-559659127580">
	  <variable>Health related quality of life specific to head and neck cancer</variable>
	  <method>European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck module HN43</method>
	  <timepoints>Baseline, post intervention, 3 month follow up</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="8a7a7095-0c0c-4353-9a09-963695d74f1b" approvalStatus="approved" statusDate="2024-03-13T00:00:00.000Z">
	  <committeeName>London-Camden &amp; Kings Cross REC</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>24/LO/0164</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12055450</doi>
      <eudraCTNumber/>
      <irasNumber>335217</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 61140, NIHR: 303061</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="69c85360-6a56-4b4c-a369-7e5921affc56" numberType="iras" canonicalSecondaryNumber="IRAS335217">335217</secondaryNumber>
	<secondaryNumber id="327e4a15-b3c9-45f6-8da4-3a60db2c7840" numberType="cpms" canonicalSecondaryNumber="CPMS61140">61140</secondaryNumber>
	<secondaryNumber id="f011c376-8f93-46b4-8d9d-6b49ab2319cc" numberType="nihr" canonicalSecondaryNumber="NIHR303061">303061</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Single</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2028-08-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3fce724a-2be9-4782-bf84-8a3e0ced8a49">
	  <name>Clatterbridge Cancer Centre</name>
	  <address>Clatterbridge Hospital
Clatterbridge Road</address>
	  <city>Wirral</city>
	  <state/>
	  <country>England</country>
	  <zip>CH63 4JY</zip>
	  <rtsId>RJR62@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="444e9c60-a674-4d3c-8eab-267e569ece7d">
	  <name>Liverpool University Hospitals NHS Foundation Trust</name>
	  <address>Royal Liverpool University Hospital
Prescot Street</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L7 8XP</zip>
	  <rtsId>REM@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="11a7c5fe-243c-40c9-9aa9-4c2eb661179a">
	  <name>Mid Cheshire Hospitals NHS Foundation Trust</name>
	  <address>Leighton Hospital
Leighton</address>
	  <city>Crewe</city>
	  <state/>
	  <country>England</country>
	  <zip>CW1 4QJ</zip>
	  <rtsId>RBT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Have a clinical diagnosis of dysphagia on instrumental assessment using videofluoroscopic swallow study or fibreoptic endoscopic evaluation of swallowing  
2. Have dysphagia indicated by outcome measures with penetration aspiration scale score at least 3 and/or DIGEST efficiency grade at least 1  
3. Have completed chemotherapy, radiotherapy and or surgical intervention with curative intent for first time diagnosis of squamous cell carcinoma of the head and neck at least 3 months previously  
4. Be able to give informed consent  
5. Be aged 18 years or above  
6. Be able to tolerate fluids orally IDDSI Level 0 to 3  
7. Exhibit a suboptimal respiratory swallow pattern exhale to inhale, inhale to inhale, or inhale to exhale in at least 20% of swallow trials
8. Be able to hold a drink orally and resume breathing</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="120.0">120 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. A nasogastric tube, laryngectomy or tracheostomy where tube presence will alter respiratory swallow coordination  
2. Known neurological disease or insult impacting on swallowing  
3. Spinal surgery or insult impacting on swallowing  
4. Chronic COPD with forced expiratory volume less than 30% on pulmonary function testing  
5. Recent history within the last 3 months of aspiration pneumonia</exclusion>
      <recruitmentStart>2026-05-06T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-02-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Swallow training in head and neck cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Development of Respiratory-Swallow Training programme (biofeedback)
A treatment manual will be developed for ReST using biofeedback using the TIDieR framework detailing: the equipment set-up, feedback provision, monitoring and measuring of goals for both interventions.
 
Respiratory Swallow Training (ReST) using biofeedback group:
Clinicians (Speech and language therapists) at the participating sites will be trained to deliver ReST using biofeedback, as per the treatment protocol. Training will include: theoretical underpinning, treatment procedure, practical application and use of instrumentation. Competency will be determined by successful (100%) identification of optimal respiratory-swallow coordination (exhale-swallow-exhale pattern) using visual feedback.
ReST training sessions with take place up to 1 hour weekly for up to 6 weeks until mastery is reached. An experienced speech and language therapist, who has received training, will deliver ReST using biofeedback to participants at an NHS clinic or the participant’s home, dependent of individual preference or clinical availability. Participants will continue to see their treating therapist as part of usual care (if applicable) whilst receiving ReST. The treatment protocol will follow a tripartite design incorporating principles of motor learning as outlined by Martin-Harris &amp; colleagues (2015). Goals will be included which are divided into sub-goals within three learning domains: 1) identification, 2) acquisition, and 3) mastery. Participants will only move onto the next phase when they have demonstrated 90% accuracy (over 10 trials) on any given goal.

1. Identification:
Participants will be presented with a series of static graphical representations of swallowing and respiration via an online programme. These graphics will show the respiratory cycles and the swallowing. Participants will be asked to identify specific targets to demonstrate their ability to recognise: (1) phases of breathing, (2) the swallow trigger, and (3) optimal versus suboptimal swallowing patterns.
Participants will then progress to viewing similar representations presented dynamically on a computer screen. To advance to the next stage, participants must correctly identify targets in at least 9 out of 10 trials. If fewer than 9 trials are correctly identified, additional practice will be provided and/or earlier learning objectives will be revisited.
This training will be delivered as an online module that can be completed either independently at home or with support from a therapist, according to participant preference.
 
2. Acquisition:
The aim of the acquisition module is for participants to be able to self-initiate swallows during the expiratory cycle. Participants will view a visual graphical representation of their own respiratory-swallow pattern on the computer screen, via respiratory Inductance plethysmography and a manual switch, which will be pressed by the therapist to mark the swallow. The clinician will provide verbal feedback to participants in relation to accuracy. Teaspoons of thin fluids will be initially trialled, providing they can be safely swallowed. If participants are unable to swallow thin fluids safely, thicker fluids will be trialled as per the findings on instrumental swallow assessment. Swallow initiation during expiration will initially be targeted (with and without visually guided feedback).  Only consistencies the participant is safely able to tolerate will be used for training (as per the instrumental swallow assessment).  Participants will need to successfully complete 9/10 trials at each stage to move on to the mastery phase.
 
3. Mastery: The aim of the mastery module is to ensure participants are able to use an optimal respiratory swallow pattern (i.e. exhale-swallow-exhale) with 90% consistency, without visual or verbal feedback. The programme will run for 5-6 weeks.
 
Usual care group:
Usual care refers to speech and language therapy provided by the treating speech and language therapist as part of routine care. Speech and language therapy (SLT) aims to remediate swallowing, speech and voice difficulties following head and neck cancer. SLT may include assessment (clinician-rated, patient-rated and instrumental), intervention and/or review, which may focus on the use of compensatory strategies, strengthening and range of motion exercises, supporting mood and confidence, working with family/carers and providing information. Therapy is individually tailored and is largely face-to-face, however it may incorporate telehealth or group work. Patients are seen as inpatients, outpatients or in the community. Dysphagia therapy may include but is not limited to: swallow exercises (e.g. effortful swallow, Masako manoeuvre, Mendelsohn manoeuvre, supra-glottic swallow) and non-swallow exercises (e.g. range of movement exercises, tongue strengthening, expiratory muscle strength training). Therapy may also focus on speech and voice training, directly targeting articulation and vocal quality.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study will be stored in a publicly available repository (University of Liverpool repository, anonymised raw data will be shared, the data will become available following study completion for a period of 10 years, consent from participants will be obtained)</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Stored in publicly available repository</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3bc7c44c-49f0-477e-a9a7-78e8affe3878" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-04-10T00:00:00.000Z" dateUploaded="2026-04-21T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="b4d7700b-ffa0-43cd-ab7f-380971622c24" originalFilename="49396 Protocol ReST-HN WP3 only 10.04.26 V1.7.pdf" downloadFilename="49396 Protocol ReST-HN WP3 only 10.04.26 V1.7.pdf" version="1.7" mimeType="application/pdf" length="624483" md5sum="a9665fcb4383342dc4700009dfd4a6ee"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>9c0210de-c34c-4430-ba6f-1563bc675a84</funderId>
      <contactId>108cfc4b-7016-4079-a219-ce0c9bb11e82</contactId>
      <sponsorId>9bf64e5e-9517-4e34-aea1-60cd9a583006</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/b4d7700b-ffa0-43cd-ab7f-380971622c24/49396">
	<description>Protocol file</description>
	<name>49396 Protocol ReST-HN WP3 only 10.04.26 V1.7.pdf</name>
	<id>b4d7700b-ffa0-43cd-ab7f-380971622c24</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>624483</length>
	<md5sum>a9665fcb4383342dc4700009dfd4a6ee</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="108cfc4b-7016-4079-a219-ce0c9bb11e82">
    <title>Dr</title>
    <forename>Michelle</forename>
    <surname>Lawton</surname>
    <orcid>https://orcid.org/0000-0002-2399-6643</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Allied Health Professions &amp; Nursing, Institute of Population Health / Liverpool Head and Neck Centre,
University of Liverpool, 1.2 Whelan Building, The Quadrangle, Brownlow Hill</address>
      <city>Liverpool</city>
      <state/>
      <country>United Kingdom</country>
      <zip>L69 3GB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">michelle.lawton@liverpool.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="9bf64e5e-9517-4e34-aea1-60cd9a583006">
    <organisation>University of Liverpool</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="9c0210de-c34c-4430-ba6f-1563bc675a84">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial></allTrials>